This invention relates to medical devices for thrombus removal, and more particularly to thrombus aspiration systems.
It is often desirable to remove tissue from the body in a minimally invasive manner as possible, so as not to damage other tissues. For example, removal of tissue (e.g., blood clots) from the vasculature may improve patient conditions and quality of life.
Many vascular system problems stem from insufficient blood flow through blood vessels. One causes of insufficient or irregular blood flow is a blockage within a blood vessel referred to as a blood clot, or thrombus. Thrombi can occur for many reasons, including after a trauma such as surgery, or due to other causes. For example, a large percentage of the more than 1.2 million heart attacks in the United States are caused by blood clots (thrombi) which form within a coronary artery.
When a thrombus forms, it may effectively stop the flow of blood through the zone of formation. If the thrombus extends across the interior diameter of an artery, it may cut off the flow of blood through the artery. If one of the coronary arteries is 100% thrombosed, the flow of blood is stopped in that artery, resulting in a shortage of oxygen carrying red blood cells, e.g., to supply the muscle (myocardium) of the heart wall. Such a thrombosis is unnecessary to prevent loss of blood but can be undesirably triggered within an artery by damage to the arterial wall from atherosclerotic disease. Thus, the underlying disease of atherosclerosis may not cause acute oxygen deficiency (ischemia) but can trigger acute ischemia via induced thrombosis. Similarly, thrombosis of one of the carotid arteries can lead to stroke because of insufficient oxygen supply to vital nerve centers in the cranium. Oxygen deficiency reduces or prohibits muscular activity, can cause chest pain (angina pectoris), and can lead to death of myocardium which permanently disables the heart to some extent. If the myocardial cell death is extensive, the heart will be unable to pump sufficient blood to supply the body's life sustaining needs. The extent of ischemia is affected by many factors, including the existence of collateral blood vessels and flow which can provide the necessary oxygen.
Clinical data indicates that clot removal may be beneficial or even necessary to improve outcomes. For example, in the peripheral vasculature, inventions and procedures can reduce the need for an amputation by 80 percent. The ultimate goal of any modality to treat these conditions of the arterial or venous system is to remove the blockage or restore patency, quickly, safely, and cost effectively. This may be achieved by thrombus dissolution, fragmentation, thrombus aspiration or a combination of these methods.
Catheter directed thrombectomy and thrombolysis are commonly perceived to be less traumatic, less likely to decrease the morbidity and mortality associated with conventional surgical techniques. In recent years, direct administration of chemical lysing agents into the coronary arteries has shown to be of some benefit to patients who have thrombosed coronary arteries. In this procedure, a catheter is placed immediately in front of the blockage and a drip of streptokinase is positioned to be directed at the upstream side of the thrombus. Streptokinase is an enzyme which is able in time to dissolve the fibrin molecule. This procedure can take several hours and is not always successful in breaking up the thrombus. Furthermore, it can lead to downstream thrombus fragments (emboli) which can lead to blockage of small diameter branches.
Thrombectomy is a technique for mechanical removal of blood clots in an artery or vein. It refers to physically removing a clot as opposed to employing chemical lysis to dissolve it. Multiple devices have been introduced to break up and remove clot and plaque, but each has its own shortcomings. Specifically, the existing systems do not provide adequate methods for breaking up the clot into smaller pieces for subsequent aspiration. Also, they do not provide a method for removing the thrombectomy device over a guidewire and reinserting into the same location to complete the procedure. Furthermore, conventional aspiration systems offer little control over the amount of blood lost during the procedure. There is a need for improved thrombectomy devices and aspiration systems that are safer and more effective for removing thrombus and plaque from the vascular system.
Aspiration systems and methods are disclosed herein for controlling blood loss during thrombus removal. The aspiration systems include, at least, an aspiration catheter, a thrombus retrieval device extending through the aspiration catheter, and an aspiration tubing fluidically coupled to the aspiration catheter. An aspiration lumen extends through the aspiration catheter and the aspiration tubing. A sensor measures a flow parameter associated with a liquid within the aspiration lumen. The aspiration systems further include a receptacle configured to collect liquid aspirated by the aspiration catheter. A vacuum line is fluidically coupled to the receptacle, and a regulator adjusts the vacuum pressure within the vacuum line. A vacuum controller is operably coupled to the sensor and the regulator. The vacuum controller is configured to receive the flow parameter from the sensor, compare the flow parameter to a target range for the flow parameter, and send an automatic control signal to the regulator based on a comparison of the flow parameter to the target range. The automatic control signal causes the regulator to adjust the vacuum pressure within the vacuum line.
In some implementations, the automatic control signal causes the regulator to decrease the vacuum pressure upon a determination that the flow parameter is above an upper limit of the target range, and to increase the vacuum pressure upon a determination that the flow parameter is below a lower limit of the target range. For example, the upper limit can be a flow rate from 70 mL per minute to 130 mL per minute, and the lower limit can be a flow rate from 0 mL per minute to 40 mL per minute. In some examples, the vacuum controller is configured to adjust the flow rate to an intermediate level, such as, for example, from 20 mL per minute to 50 mL per minute. Increases and decreases in vacuum pressure can occur in a stepwise manner. In some implementations, the vacuum controller can activate an aspiration program that causes increases and decreases of vacuum pressure in a stepwise manner. In some examples, the aspiration program is activated upon receipt of information from one or more manual inputs in communication with the regulator, the vacuum controller, or both.
The receptacle is fluidically coupled to the aspiration tubing, the aspiration catheter, and the vacuum line. In some implementations, an intake port on the receptacle provides the coupling between the receptacle and the aspiration tubing, and a vacuum port on the receptacle provides the coupling between the receptacle and the vacuum line. The receptacle can include a receptacle vent in communication with the regulator or the vacuum controller. The receptacle vent opens upon receipt of a venting signal from the regulator or vacuum controller.
The aspiration system includes one or more sensors for measuring flow parameters, such as, for example, a flow rate. Some implementations can include a plurality of sensors configured to measure one or more parameters associated with fluid flow at disparate points along a length of the aspiration lumen, and to send the measured parameters to the vacuum controller. The sensor may or may not contact the liquid within the aspiration lumen.
Some implementations can further include an air leak sensor in communication with the vacuum controller or the regulator. The air leak sensor can detect air flow through the aspiration tubing and send a leak signal to the vacuum controller, the regulator, or the vacuum pump upon detection of air through the aspiration tubing. The vacuum controller, regulator, or pump can slow or stop the vacuum flow while the air leak is addressed. In some implementations, the vacuum controller is configured to delay detection of air leaks during a vacuum initialization period. Alternatively, or in addition, the vacuum controller can be configured to delay controlling the vacuum in response to detection of air leaks during a vacuum initialization period.
In some implementations of the system, the regulator adjusts the vacuum pressure within the vacuum line by manipulating a valve that opens the vacuum line to the atmosphere. In some implementations, the regulator adjusts the vacuum pressure within the vacuum line by manipulating a valve that alters the flow capacity of the vacuum line. The vacuum line can have a disposable portion and a reusable portion. The disposable portion can be coupled to the reusable portion at a connector. Some implementations of the system include a vacuum pump. Some implementations can include a power sensor configured to synchronize the delivery of power between the pump and the vacuum controller.
The vacuum controller sends signals to one or more components of the system to regulate flow of air in the vacuum line and blood through the aspiration lumen. The vacuum controller can be, in some examples, a microprocessor controller. It can include an analog to digital converter and a digital to analog converter. In some examples, the vacuum controller is configured to measure a frequency from the flow parameter. The vacuum controller can operate independently. For example, the vacuum controller is capable of operating without input from external sources such as a computer.
Some implementations of the systems include one or more manual inputs in communication with the vacuum controller, the regulator, and/or a receptacle vent. The manual input is configured to accept a manual command and send a first manual control signal responsive to the manual command to one or more of the vacuum controller, the regulator, and/or the receptacle vent. In some examples, upon receipt of the first manual control signal, the vacuum controller stops one or more steps of comparing the flow parameter to a target range for the flow parameter, forming an automatic control signal, and/or sending the automatic control signal to the regulator. In some implementations, the vacuum controller is configured to send a second manual control signal to the regulator and/or receptacle vent based on the first manual control signal. The regulator controls the vacuum pressure within the vacuum line upon receipt of the first manual control signal and/or the second manual control signal. The receptacle vent opens or shuts upon receipt of the first manual control signal and/or the second manual control signal. Some systems can also include an indicator in communication with the flow sensor. The indicator is configured to inform a user of a characteristic of the flow parameter.
In some implementations, at least one braided assembly extends over a distal region of the thrombus retrieval device. The braided assembly can include a braid having a shape memory of a collapsed configuration.
In some implementations, the aspiration system further comprises a clamp coupled to the aspiration tubing and a switch operably coupled to the clamp, the switch comprising a closed configuration and an open configuration, wherein the switch in the closed configuration causes the clamp to stop fluid flow through the aspiration tubing, and wherein the switch in the open configuration causes the clamp to allow fluid flow through the aspiration tubing. The switch can be in communication with the vacuum controller and/or the regulator. Shifting the switch to the open configuration can send a surge protection signal to the regulator and/or to the vacuum controller. The regulator and/or the vacuum controller can reduce the vacuum pressure upon receipt of the surge protection signal.
Methods of controlling blood loss during thrombus removal are disclosed herein. The methods include positioning an aspiration catheter within the vascular system of a subject and positioning a thrombus retrieval device within the vascular system of the subject through the aspiration catheter. The aspiration catheter is fluidically connected to an aspiration tubing and a vacuum pump. Activation of the vacuum pump initiates the flow of blood through the aspiration catheter and the aspiration tubing. A sensor measures a flow parameter of the blood within the aspiration tubing. The flow parameter from the sensor is received at a vacuum controller. The flow parameter is compared to a target range for the flow parameter, and an automatic control signal is sent to the regulator based on a comparison of the flow parameter to the target range. The vacuum pressure within the vacuum line is adjusted according to information stored in the automatic control signal.
In some implementations, the vacuum pump is activated at full power, and adjustments to the vacuum pressure are regulated by the vacuum controller while the vacuum pump runs at full power.
The step of adjusting the vacuum pressure can include decreasing the vacuum pressure upon a determination that the flow parameter is above an upper limit of the target range (for example, an upper limit of a flow rate from 70 mL per minute to 130 mL per minute). The step of decreasing the vacuum pressure can include lowering the vacuum pressure in a stepwise manner. In some implementations, the vacuum pressure is decreased until the measured flow parameter reaches an intermediate level flow rate of 20 mL per minute to 50 mL per minute. Some methods include a step of activating an aspiration program upon receipt of a manual command from one or more manual inputs in communication with the regulator and/or the vacuum controller, and the aspiration program includes lowering the vacuum pressure in a stepwise manner.
The step of adjusting the vacuum pressure can include increasing the vacuum pressure upon a determination that the flow parameter is below a lower limit of the target range (for example, a lower limit of a flow rate of from 0 mL per minute to 50 mL per minute). the step of increasing the vacuum pressure can include raising the vacuum pressure in a stepwise manner. In some implementations, the vacuum pressure is raised until the measured flow parameter reaches an intermediate level flow rate of 20 mL per minute to 50 mL per minute. Some methods include a step of activating an aspiration program upon receipt of a manual command from one or more manual inputs in communication with the regulator and/or the vacuum controller, and the aspiration program includes raising the vacuum pressure in a stepwise manner.
In some implementations, the step of adjusting the vacuum pressure within the vacuum line comprises manipulating a valve that opens the vacuum line to the atmosphere. In some implementations, the step of adjusting the vacuum pressure within the vacuum line alters the flow capacity of the vacuum line.
The step of measuring a flow parameter can include measuring a flow rate. Some method implementations use a plurality of sensors to measure one or more flow parameters of the blood at disparate points along the length of the aspiration lumen. The one or more flow parameters are received at the vacuum controller. The methods can further include a step of measuring a frequency from the flow parameter at the vacuum controller.
Some method implementations can include a step of detecting air within the aspiration tubing and sending a leak signal to the regulator, the pump, or to the vacuum controller. In some implementations, the step of detecting air within the aspiration tubing or the step of sending a leak signal to the regulator or the pump is delayed during initialization of the vacuum.
Some method implementations can include a step of accepting a manual command at a manual input and sending a first manual control signal responsive to the manual command to one or more of the vacuum controller, the regulator, or a receptacle vent. Upon receipt of the first manual control signal, the vacuum controller can stops sending automatic control signals to the regulator. In some implementations, a second manual control signal is formed at the vacuum controller (based on the first manual control signal) and the second manual control signal is sent to the regulator and/or receptacle vent. Some method implementations can include a step of receiving the first manual control signal or the second manual control signal at the regulator and controlling vacuum pressure within the vacuum line based on the first manual control signal or the second manual control signal. Some method implementations can include a step of receiving the first manual control signal or the second manual control signal at the receptacle vent and opening or shutting the vent based on the first manual control signal or the second manual control signal.
Some method implementations can include a step of receiving information from the flow sensor at an indicator and informing a user of a characteristic of the flow parameter using the indicator.
Some method implementations can include a step of shifting a switch from a closed configuration to an open configuration, wherein shifting the switch to the open configuration causes a clamp coupled to the aspiration tubing to allow fluid flow through the aspiration tubing. A surge protection signal can be sent upon shifting of the switch to the open configuration and received at the controller or regulator. The vacuum pressure can be decreased upon receipt of the surge protection signal.
Some method implementations can include a step of synchronizing the delivery of power between the vacuum pump and the vacuum controller.
The device is explained in even greater detail in the following drawings. The drawings are merely exemplary and certain features may be used singularly or in combination with other features. The drawings are not necessarily drawn to scale.
The systems and methods disclosed herein aim to reduce the amount of blood lost during procedures that utilize aspiration to remove thrombus from the vasculature. The systems include a vacuum controller for an aspiration pump that is used in conjunction with an aspiration catheter and an aspiration tubing. The aspiration tubing is equipped with a flow sensor in communication with vacuum controller. The vacuum controller monitors the flow rate of blood being aspirated by the pump and communicates with a vacuum regulator to raise the vacuum if the flow rate gets to low (for example, when obstructed by a clot). The vacuum controller also communicates with the vacuum regulator to lower the vacuum if the flow rate gets too high. This lowering of the vacuum is a safety feature designed to prevent the system from aspirating blood instead of clot. Applying only the vacuum needed to remove the clot prevents unnecessary blood loss. Furthermore, damage to the vasculature is reduced because the amount of time the system applies full vacuum is minimized. The system can increase or decrease pressure gradually, or in a stepwise manner, to ensure the practitioner has sufficient time to respond to sudden changes in flow rate. The system can also include a variety of manual inputs to slow, pause, or stop the automated flow control processes.
The system disclosed herein integrates flow and vacuum control, using flow rate to inform the desired vacuum level. Conventional systems do not offer this feature. Many prioritize improving aspiration efficiency over controlling blood loss. Furthermore, conventional systems often adjust vacuum level based on pressure sensors within the aspiration tubing. Because the disclosed system responds specifically to the parameter of interest—the amount of blood flowing through the catheter—it responds more accurately than pressure measurement-based systems. With this system, the user can tune the flow rate, defining minimum and maximum allowed flow rates, and then automate control of the vacuum and flow rate according to those thresholds. This automation reduces the need for the practitioner to monitor and adjust the procedure for blood loss (though the practitioner is able to override the automation when necessary, via the aforementioned manual inputs). Advantageously, the system minimizes the necessary procedure time by optimizing the aspiration process.
The aspiration system can be used with a variety of catheters and vacuum pumps without changing the core aspiration system. It can be provided with all of the necessary components, or can be used with components that are provided by the clinician. Furthermore, the vacuum controller, regulator, and pump can be used in the operating theater but fluidically isolated from the patient, negating the need for extensive sterilization. Flow manipulation occurs within the vacuum line instead of the aspiration lumen—a cleaner design than some conventional systems where valves directly manipulate blood flow within the aspiration lumen. In the disclosed aspiration systems, components that do contact blood can be disposable, whereas fluidically isolated components can be reusable.
The thrombectomy devices disclosed herein remove a thrombus using a braided assembly that can be expanded to a diameter of the practitioner's choosing, enabling the practitioner to custom fit the device to the particular vessel and thrombus and during the procedure. Unlike conventional thrombectomy devices, the diameter of the disclosed braided assembly can be changed mid-procedure as needed. For example, the braided assembly can be opened to a wider diameter to apply more outward force against the thrombus should additional grip be needed for its removal. In some implementations, multiple braided assemblies can be used to address longer thrombi. Each braided assembly can be separately expanded, such that the individual assemblies have different diameters during the procedure.
The device disclosed herein is used to the remove a thrombus, clot, or plaque from the veins or arteries of the body. It includes an aspiration catheter and a retrieval device that extends through the lumen of the aspiration catheter. An expandable braided assembly extends over a distal region of the retrieval device, such that when the retrieval device exits the distal end of the aspiration catheter, the braided assembly is positioned outside of the aspiration catheter. An activation wire extends through the lumen of the retrieval device. The distal end of the activation wire exits the retrieval device at an exit point to connect to and control the expansion of a braided assembly. On the proximal end, the activation wire is attached to a tensioning element. Applying tension to the activation wire causes the braided assembly to expand to a diameter of the practitioner's choosing. For example, the practitioner may apply a first level of tension to deploy the braided assembly to a first, partially expanded configuration and then later decide to widen the diameter to the fully expanded configuration by applying a greater level of tension to the activation wire. The expanded braided assembly contacts the thrombus, clot, or plaque and is pulled proximally toward the aspiration catheter to assist in removal. Hereinafter the device and methods will be described as removing (or being configured to remove) a thrombus. However, it will be understood that the device can also be used to remove clots or plaques from the vasculature with no structural (or only slight structural) modifications. Various implementations of the thrombectomy catheter include a retrieval device with multiple braided assemblies, multiple activation wires, multiple braided sections of a single braided assembly, and retrieval devices with multiple lumens to, for example, enable use with a guidewire.
The following description of certain examples of the inventive concepts should not be used to limit the scope of the claims. Other examples, features, aspects, configurations, implementations, and advantages will become apparent to those skilled in the art from the following description. As will be realized, the device and/or methods are capable of other different and obvious aspects, all without departing from the spirit of the inventive concepts. Accordingly, the drawings and descriptions should be regarded as illustrative in nature and not restrictive.
For purposes of this description, certain advantages and novel features of the aspects and configurations of this disclosure are described herein. The described methods, systems, and apparatus should not be construed as limiting in any way. Instead, the present disclosure is directed toward all novel and nonobvious features and aspects of the various disclosed aspects, alone and in various combinations and sub-combinations with one another. The disclosed methods, systems, and apparatus are not limited to any specific aspect, feature, or combination thereof, nor do the disclosed methods, systems, and apparatus require that any one or more specific advantages be present or problems be solved.
Although the operations of exemplary aspects of the disclosed method may be described in a particular, sequential order for convenient presentation, it should be understood that disclosed aspects can encompass an order of operations other than the particular, sequential order disclosed. For example, operations described sequentially may in some cases be rearranged or performed concurrently. Further, descriptions and disclosures provided in association with one particular aspect or implementation are not limited to that aspect or implementation and may be applied to any aspect or implementation disclosed. It will understood that various changes and additional variations may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention or the inventive concept thereof. Certain aspects and features of any given aspect may be translated to other aspects described herein. In addition, many modifications may be made to adapt a particular situation or device to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular implementations disclosed herein, but that the invention will include all implementations falling within the scope of the appended claims.
Features, integers, characteristics, compounds, chemical moieties, or groups described in conjunction with a particular aspect, configuration, implementation or example of the invention are to be understood to be applicable to any other aspect, configuration, implementation, or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract, and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing aspects. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract, and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. The terms “about” and “approximately” are defined as being “close to” as understood by one of ordinary skill in the art. In one non-limiting aspect the terms are defined to be within 10%. In another non-limiting aspect, the terms are defined to be within 5%. In still another non-limiting aspect, the terms are defined to be within 1%.
“Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
The terms “coupled,” “connected,” and the like as used herein mean the joining of two members directly or indirectly to one another. Such joining may be stationary (e.g., permanent) or moveable (e.g., removable or releasable). Such joining may be achieved with the two members or the two members and any additional intermediate members being integrally formed as a single unitary body with one another or with the two members or the two members and any additional intermediate members being attached to one another.
The terms “proximal” and “distal” as used herein refer to regions of the aspiration tubing or thrombectomy device. “Proximal” means a region closest to the practitioner during a procedure, while “distal” means a region farther from the practitioner during a procedure.
Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps. “Exemplary” means “an example of” and is not intended to convey an indication of a preferred or ideal aspect. “Such as” is not used in a restrictive sense, but for explanatory purposes.
A vacuum is a pressure that is less than the local atmospheric pressure. As used herein, “vacuum pressure” indicates the relative pressure, i.e., the differential between ambient pressure and the absolute pressure applied by the vacuum. Thus, an increase in relative vacuum pressure is an increase in the difference between ambient pressure and the absolute vacuum pressure, which increases the force applied by the vacuum. Likewise, a decrease in relative vacuum pressure is a decrease in the difference between ambient pressure and the absolute vacuum pressure, which decreases the force applied by the vacuum.
The braided assembly 102 is moveable from a collapsed to an expanded configuration. An example of a braided assembly 102 in an expanded configuration is shown in
The opposite end of braid 9 is welded, bonded, or otherwise adhered to slidable collar 108. In the implementations shown, the slidable collar 108 is slidably connected to the retrieval device 3 by virtue of its annular shape, which extends circumferentially around the retrieval device 3. The slidable collar 108 slides longitudinally along the retrieval device 3 as braid 9 is expanded and collapsed. The slidable collar 108 can be positioned distally to the fixed attachment point 101 (a distal position), as shown in
The braid 9 is composed of multiple strands of wire. The braid 9 takes an elliptical or a spindle shape when expanded, having a maximum diameter dmax at or near the center of the braid 9 and narrowing as the braid approaches the fixed attachment point 101 and the slidable collar 108. The wires are formed of a shape memory material such as, but not limited to, shape memory polymers or shape memory metals (e.g., nitinol). The braid 9 has a baseline shape memory of the collapsed configuration, which forms a cylindrical structure around the retrieval device 3, as shown in
When the practitioner is pulling a thrombus or plaque proximally toward aspiration catheter 106 using braided assembly 102, the braid 9 encounters distally oriented drag forces that are strongest along the widest portions (for example, the central region of the braid adjacent dmax). These drag forces resist the proximally oriented pulling force exerted by the practitioner. The distal end of braid 9 at slidable collar 108 will encounter less drag force while being pulled proximally because the radial force it exerts on the radially adjacent vasculature or thrombus is small, negligible, or non-existent. If the braid is not properly designed, the sliding collar 108 and distal end of the braid 9 will invert into the wider, central regions of the braid 9. Inversion during the procedure can be prevented by optimizing factors such as the pic count (crosses per inch), the wire diameter, the number of wires, and the ply of the braid (sets of overlapping braids). Higher pic counts increase flexibility, while lower pic counts increase longitudinal stiffness. Likewise, a braid with more than one ply (multiple sets of braids nested within each other), will be stiffer than a single-ply braid. Braids can be one-ply, two-ply, three-ply, or more. Braids with more wires will be stiffer than those with fewer wires, and braids with wider diameter wires will be stiffer than those with narrow diameter wires. Wires of varying diameters can be used within the same braid 9.
The design of the braided assemblies 102 disclosed herein may vary based on whether the device 1 is intended for an arterial procedure or for a venous procedure, since the procedure site will be wider in a venous setting. For example, a braid 9 designed for a venous application may have a dmax of from about 0.8 inches to 1.2 inches, including about 0.8 inches, about 0.9 inches, about 1.0 inch, about 1.1 inches, and about 1.2 inches. For venous applications, a braid 9 may have a wire diameter range from about 0.005 inches to about 0.02 inches, including 0.005 inches, 0.0075 inches, 0.01 inches, 0.0125 inches, 0.015 inches, 0.0175 inches, and 0.02 inches. Different wires of the braid 9 may have different diameters, or they may have the same diameter. In some venous implementations, the diameters of the wires of the braid 9 are 0.01 inches, 0.0125 inches, and/or 0.015 inches. Two-ply braids can utilize smaller wire diameters without sacrificing the radial force that can be applied. The pic count can be from 2 to 6 for venous applications. In some implementations used in venous applications, the pic count is 3, 4, or 5. The number of wires per braid for a venous application can be anywhere from 8 to 40, including 8, 16, 24, 32, and 40.
Braids for venous applications were tested using a selection of the above listed venous application parameters. End points included the expansion force and the radial outward force applied by the braid to the inner surface of a tubing that simulates a vein (the tubing having an inner diameter of 24 millimeters). The expansion force is the force required to open the braid, as applied to the activation wire. The data is shown below in Table 1.
For arterial applications, the braid 9 can have dmax of from about 0.1 inches to about 0.4, including about 0.1 inches, about 0.12 inches, about 0.14 inches, about 0.18 inches, about 0.2 inches, about 0.22 inches, about 0.24 inches, about 0.28 inches, about 0.3 inches, about 0.32 inches, about 0.34 inches, about 0.36 inches, about 0.38 inches and about 0.4 inches. For example, the braid 9 can have a dmax of about 0.28 inches, 0.3 inches, or 0.31 inches. The diameter of the wires of the braid 9 for an arterial application can range from about 0.001 inches to about 0.007 inches, including about 0.001 inches, about 0.002 inches, about 0.003 inches, about 0.004 inches, about 0.005 inches, about 0.006 inches, and about 0.007 inches. Different wires of the braid 9 may have different diameters, or they may have the same diameter. In some arterial implementations, the diameters of the wires of braid 9 are 0.003 inches, 0.004 inches and/or 0.005 inches. Two-ply braids can utilize smaller wire diameters without sacrificing the radial force that can be applied. The pic count can be from 5 to 30 for arterial applications, including a pic count of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 117, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30. In some implementations used in arterial applications, the pic count is 10, 12, or 15. The number of wires per braid 9 for an arterial application can be anywhere from 8 to 54, including 8, 16, 24, 32, 40, 48, and 54. In some implementations, the number of wires per braid 9 for an arterial application is 26, 24, or 30.
Braids for arterial applications were tested using a selection of the above listed arterial application parameters. End points included the radial outward force applied by the braid to the inner surface of a tubing (the tubing having an inner diameter of 6 millimeters), and the proximal force needed to pull the braid through a restriction in the tubing (the inner diameter of the restriction being 4 millimeters). The tubing and the restriction simulate an artery and a thrombus/plaque, respectively. Favorable prototypes give a high radial outward force without requiring excessive force to pull the braid through the restriction. The data is shown below in Table 2. All braids tested were one-ply.
The activation wire 105 extends through the lumen of the retrieval device 3, exits the retrieval device 3 at exit point 11, and extends distally along the exterior surface of the retrieval device 3. The distal end 13 of the activation wire 105 is attached to slidable collar 108. As such, the activation wire 105 is able to control the expansion and collapse of the braid 9 via the slidable collar 108. The distance between exit point 11 and slidable collar 108 affects the length that the slidable collar can be pulled along retrieval device 3 to open the braided assembly 102. If it is too close to slidable collar, the braided assembly 102 will not be able to open fully. As such, exit point 11 should be positioned proximally far enough from the unexpanded position of slidable collar 108 to enable the braided assembly 102 to open to its maximum outer diameter.
The proximal region of activation wire 105 (not shown) may be tensioned and released to control the expansion and collapse of the braided assembly 102 via movement of slidable collar 108. Under tension, the activation wire 105 moves proximally within the lumen of the retrieval device 3 as it translates the tension from the proximal region of the activation wire 105 to the braided assembly 102. In implementations where the slidable collar 108 is in the distal position (as shown), the exit point 11 of the activation wire is located proximally to the slidable collar 108. The exit point 11 can be, for example, a portal in the sidewall of retrieval device 3. Use of a slidable collar 108 to expand the braided assembly 102 is advantageous because the distal end of the braided assembly 102 can be moved while the distal region 5 of the retrieval device 3 maintains a constant position within the vasculature. Maintaining a constant position of the distal region 5 of retrieval device 3 is advantageous because sliding proximal/distal movement of the distal region 5 within the vessel can result in vessel damage or perforation.
In implementations where the slidable collar 108 is in the proximal position relative to the fixed attachment point (not shown), the activation wire 105 extends distally past the slidable collar 108 inside the retrieval device 3, exits the retrieval device 3 at exit point 11, then doubles back and extends along the exterior surface of the retrieval device 3 to attach to the proximally located slidable collar 108. The exit point 11 can be a portal in the sidewall of the retrieval device as described above, or the exit point 11 can be the distal end 107 of the retrieval device 3.
Retrieval device 3 can include a proximal hypotube 100 and a distal support tube 104, as shown in
In some implementations, distal support tube 104 has greater flexibility than the proximal hypotube 100. For example, the distal support tube 104 can be made of a polymer material, while the proximal hypotube 100 is made of a more rigid metal material. In some implementations, the proximal hypotube 100 is constructed from metal hypodermic needle tubing. The hypotube 100 can be up to 50 times stiffer than the support tube 104. There are several advantages to having a distal support tube 104 with greater flexibility than proximal hypotube 100. The greater flexibility of the support tube 104 enables a gradual transition in flexibility between the hypotube 100 and the guidewire tip 103. In some scenarios, the greater flexibility of the distal support tube 104 can facilitate movement of the braided assembly 102 through a tortuous thrombus. The greater flexibility can promote kink resistance. The greater flexibility of the distal support tube 104 can also facilitate the introduction of a portal or exit point 11 during the production of the device. The higher rigidity of the hypotube 100 (as compared to support tube 104) is important because it allows the retrieval device 3 to be pushed through the vasculature. The rigidity of hypotube 100 also helps to ensure that the braided assembly 102 can be pushed through a thrombus or plaque.
On the proximal end, the activation wire 105 can be attached to a tensioning element (not shown) that allows the activation wire 105 to be moved forward or retracted backward within the retrieval device 3. Applying tension to the activation wire 105 causes the slidable collar 108 to move and causes the braided assembly 102 to expand to a diameter of the practitioner's choosing. Similarly, releasing tension on the activation wire 105 allows the braided assembly 102 to relax into the collapsed, baseline configuration.
In some implementations, such as the one shown in
In some implementations, aspiration catheter 106 terminates in an adapter, such as adapter 204 shown in
Another implementation of a proximal handle 128 is shown in
Conventional thrombectomy devices utilize shape memory elements with a baseline expanded configuration. These conventional devices risk inadvertent overexpansion and damage to the vessel. Furthermore, conventional devices are often restrained by a bulky overlying sheath, which is pulled back to allow the device to self-expand.
Advantageously, using a device with a shape memory of the collapsed position reduces the risk of overexpansion and injury during self-expansion. Self-collapse also allows the device to be restrained using the low-profile activation wire system described herein. An additional advantage is the ability to expand the braided assembly to various diameters to precisely custom fit the size of the vessel. This can be especially useful if the size of the vessel is different than originally anticipated. The level of grip between the braid 9 and the surrounding thrombus can also be customized as needed by applying different levels of tension to the activation wire 105. For example, the practitioner may apply a first level of tension to deploy the braided assembly 102 to a first expanded outer diameter to contact the thrombus. If the force between the thrombus and the braid 9 is not enough to pull the thrombus toward the aspiration catheter 106, the practitioner can widen the braid 9 to a second expanded outer diameter by applying a greater second level of tension to the activation wire 105. This widened diameter provides a greater contact force between the thrombus and the braid 9, such that the thrombus can be more easily pulled toward aspiration catheter 106.
As with the previously described implementations, the braids of the implementation shown in
In some implementations, braids of separate braided sections or separate braided assemblies can have different properties, such as different maximum expanded diameters, different wire sizes, different wire densities, different numbers of wires, etc. These properties can vary depending upon the positioning of the braided section or the braided assembly along the retrieval device. For example, the distal braided section or braided assembly might have a larger expanded diameter to better pull back against the thrombus, while the proximal braided section(s) or braided assembly(s) might be less dense and stronger to better engage the middle of the thrombus.
Methods of performing thrombectomy procedures are also disclosed herein. An example method is illustrated in
The ability to open the braided assembly to a range of different diameters is useful to thrombectomy procedures for multiple reasons and in multiple scenarios. The ability to custom fit the braid to a particular vessel during the procedure is preferable over introducing a braid that expands to a predetermined size, then discovering mid-procedure that it is either too small to grip the thrombus or that it is too large and has damaged the vessel. As another exemplary advantage, the level of grip between the braid and the thrombus can be optimized mid-procedure. For example, the practitioner may apply a first level of tension to the activation wire to deploy the braided assembly to a first expanded outer diameter to contact the thrombus. If the force between the thrombus and the braid is not sufficient to pull the thrombus toward the aspiration catheter, the practitioner can widen the braid to a second expanded outer diameter by applying a greater second level of tension to the activation wire. This widened diameter increases the contact force between the thrombus and the braid, such that the thrombus is more easily pulled toward aspiration catheter.
The methods can also be performed using a guidewire. For example, the guidewire can be positioned distal to the thrombus prior to advancing the distal end of the retrieval device. The retrieval device extends at least partially through a lumen of the guidewire tubing, such as in the implementation of
Long thrombi can be addressed using braided assemblies with multiple braided sections such as the implementation shown in
The aspiration systems and methods disclosed herein are configured to control blood loss during thrombus removal. An example aspiration system 201 is shown in
The aspiration tubing 203 is coupled to one or more sensors 211. (If aspiration catheter 106 is directly attached to receptacle 205, the sensors 211 are coupled to the catheter 106.) A sensor 211 is configured to measure a flow parameter associated with a liquid within the lumen of the aspiration tubing 203 (such as the flow rate, for example). The sensor 211 is operably connected to a vacuum controller 213, for example, via wiring 215 to 4-pin connector 217 (or any suitable connector). The vacuum controller 213 is also operably coupled to a regulator 219, for example, via wiring 220, and regulator 219 is coupled to vacuum line 207. The regulator 219 is configured to adjust the vacuum pressure within the vacuum line 207.
When the vacuum controller 213 receives the flow parameter from sensor 211, it compares the flow parameter to a desired target range and sends an automatic control signal to the regulator 219, based on the comparison of the flow parameter to the target range. The automatic control signal causes the regulator 219 to adjust the vacuum pressure within vacuum line 207. For example, the automatic control signal can cause the regulator 219 to reduce the vacuum pressure upon a determination that the flow parameter is above an upper limit of the target range, or to decrease the vacuum pressure upon a determination that the flow parameter is below a lower limit of the target range. The vacuum controller 213 and the regulator 219 can optionally communicate in a feedback loop to regulate the vacuum pressure, wherein the vacuum controller 213 communicates a control signal to the regulator 219 and the regulator 219 communicates the current vacuum pressure back to the vacuum controller 213. In one example, communication from the regulator 219 to the vacuum controller 213 can be accomplished via wiring 221. These components and operations will be discussed in greater detail, below.
The vacuum pump 209 can be a standard medical suction pump conventionally used in hospitals, outpatient surgery centers, and clinical practices. As one example, the vacuum pump 209 can be a Basic Suction Pump (Medela AG, Baar, Switzerland), which has piston-cylinder based drive unit and mechanical overflow to protect the pump. The Medela Basic Suction pump has a max flow rate of 300 mL/min and a maximum vacuum of 90 kPa below ambient pressure. However, the make or model of vacuum pump 209 is not limited—it can be any type available in clinical settings. The vacuum pump 209 can be provided by the user, or it can be provided as part of a kit with some or all of the other components shown in
The aspiration tubing 203 is coupled to the receptacle 205 at an intake port 223, and the vacuum line 207 is coupled to the receptacle 205 at the vacuum port 225. The aspiration tubing 203, receptacle 205, and vacuum line 207 can be any make or model. The sizes and materials can be adapted to suit the needs of the particular procedure. These components can be provided by the user, or they can be provided as part of a kit with some or all of the other components shown in
As discussed above, regulator 219 communicates with vacuum controller 213 to control the pressure in vacuum line 207. In one example, the regulator is an ITC 2090. As one example, the regulator 219 include can have a valve that opens the vacuum line 207 to the atmosphere, thus decreasing the vacuum pressure by venting the system. As another example, regulation of flow can be achieved by incorporating an adjustable flow valve, which may widen or narrow the vacuum line 207b to alter the flow capacity (i.e., direct flow control). Notably, handling flow adjustments on the vacuum side (i.e., to the left of the arrow in
The flow sensor 211 can be in direct contact with the liquid in the aspiration tubing 203, or it can be configured for contactless sensing. For example, in some implementations, the flow sensor 211 is a paddle-wheel style sensor positioned within the aspiration lumen 216. A paddle-wheel style sensor sends turn frequency measurements to the vacuum controller 213, which determines the flow rate accordingly. Alternatively, the flow sensor 211 can be an ultrasonic sensor, a laser-based sensor, an infrared sensor, or some other optical based sensor, measuring the flow parameters through the walls of aspiration tubing 203 without contacting the blood. These have the benefit of being reusable, but are typically costlier than a contact-based sensor. While a single sensor 211 is shown in
Adapter 204 shown in
The air leak sensor 214 can communicate a leak signal to the vacuum controller 213, the regulator 219, or directly to the vacuum pump 209, at which point the vacuum controller 213, the regulator 219, or the pump 209 slows or stops the vacuum flow while the air leak is addressed, reducing blood loss. In some implementations, there is a leak detection delay during initialization of the vacuum. The leak detection delay prevents the aspiration of the initial air in the tube—otherwise, the air leak sensor may detect it as a leak.
As shown in
The system provide for one or more manual override options, which may communicate a complete shut-off of the vacuum or aspiration flow, a scaled diminishing of the vacuum or aspiration flow, a reactivation of vacuum or aspiration flow, or a scaled increasing of the vacuum or aspiration flow. The manual commands are accepted at one or more manual inputs, such as, but not limited to, clamps, switches, buttons, sliders, knobs, pedals or a digital user interface. In some examples, a clamp 231 can be coupled to the aspiration tubing 203 to enable the practitioner to manually stop the flow of blood through the aspiration tubing 203, overriding the automated system. Alternatively or additionally, a manual override switch or button can communicate with the regulator 219 to fully open the valve to atmospheric pressure, thereby releasing the pressure in the vacuum line 207. As an alternative to a binary switch or button that fully releases the vacuum, sliders, knobs, or the like can be used to diminish or increase the vacuum force gradually. As another alternative, a foot pedal (not shown) can be activated to shut down or slow the flow either at the clamp 231, the regulator 219, or the pump 209 (or reactivate and increase the flow at any of those components). In some implementations, a manual override option can be provided at a user interface 229 (including manual or digital switches, sliders or knobs). Finally, the user has the option to turn the vacuum on and off at the vacuum pump 209, or gradually adjust its strength.
Triggering a manual override option can induce a first manual control signal to be sent from the manual input to the vacuum controller. The first manual control signal can cause the vacuum controller 213 to stop performing the step of comparing the flow parameter to the target range, or to stop the step of forming the automatic control signal, or to stop the step of sending the automatic control signal to the regulator. The vacuum controller 213 can instead send a second manual control signal to the regulator 219 based on the manual input (information from the first manual control signal). Alternatively, triggering a manual override option can send a manual control signal from the manual input directly to the regulator 219 to raise or lower the vacuum pressure in the vacuum line 207. Likewise, the manual input can be triggered to reactivate any or all of these processes.
In some implementations, the receptacle 205 can include a receptacle vent 210 in communication with the vacuum controller 213, the vacuum pump 209, the regulator 219, or with one or more of the manual inputs. Any one of the above-listed manual override actions can trigger a receptacle venting signal to be sent to the receptacle vent 210, directly or via the vacuum controller 213. The vent receives the receptacle venting signal and opens to equilibrate the pressure in the receptacle 205 with atmospheric pressure. This action eliminates residual pressure in the receptacle 205 that might otherwise cause the suction of additional blood after the manual override action. In some aspects, the venting signal may be a manual control signal sent by the vacuum controller 213 or regulator 219 upon activation of one or more manual inputs (for example, a manual command to override the vacuum system).
The clamp 231 can be coupled to tubing between the aspiration tubing 203 and the receptacle 205 and can be activated by a switch 233 for ease of use. The switch 233 can have an open configuration and a closed configuration. In the closed configuration, the switch tells the clamp 231 to close off the flow to the receptacle 205. In the open configuration, the switch 233 tells the clamp 231 to open the catheter 203 and allow blood to flow into receptacle 205. However, closure of clamp 231 can cause vacuum pressure to build up in the vacuum line 207. Opening the clamp 231 can thus cause a sudden surge and suction of blood. To avoid this, the switch 233 can be in operable communication with either the vacuum controller 213 or the regulator 219 (for example, via wiring 235). The shifting of switch 233 to the open configuration sends a surge signal to the regulator 219, either directly or via vacuum controller 213 as shown in
Some examples of the system include a user interface 229. The user interface 229 can optionally be a touch screen, or it can be in communication with a keyboard. Regardless, the user interface can be configured to accept manual input. The user interface 229 can be in communication with the vacuum controller 213 or with the regulator 219, and is configured to send manual control signals to the vacuum controller 213 or the regulator 219 responsive to the manual input. For example, the user can adjust the upper and lower limits of the target range and/or the time delay in triggering a vacuum change (for example, how long the flow rate is permitted to be at or above the upper limit before the vacuum pressure is decreased). The user interface can include a manual override button that allows the user to stop automated control and manually set the flow rate through the aspiration tubing 203. The user interface 229 can also include readouts to inform the user of the instantaneous flow rate through the aspiration tubing 203, and/or the total blood collected at receptacle 205.
Communication between the components of aspiration system 201 can take occur via any suitable communication link that facilitates data exchange between the components. Communication links can include wired, wireless, and optical links. Example communication links include, but are not limited to, a local area network (LAN), a wireless local area network (WLAN), a wide area network (WAN), a metropolitan area network (MAN), Ethernet, the internet, or any other wired, or wireless link such as WiFi, WiMax, 3G, 4G, or 5G. As shown in
The vacuum controller 213 can advantageously be a microprocessor that operates independently of a larger computer system. For example, vacuum controller 213 can be a complex instruction set microprocessor, a reduced instruction set microprocessor, a superscalar processor, an application specific integrated circuit, or a digital signal multiprocessor. The vacuum controller 213 is configured to measure frequency from the flow parameter received from sensor 211, and includes an analog to digital converter and a digital to analog converter. Power source 239 can be any suitable power source, and can be external to the vacuum controller 213 (such as a wall outlet) or internal to the vacuum controller 213 (such as a battery).
In some implementations, power sensors 240 can be included on the pump 209 and/or the vacuum controller 213 in order to synchronize the delivery of power between the two components. That is, when one of the two components (pump 209 or vacuum controller 213) is powered off, the power sensor 240 on the other of the two components detects the power change and is automatically powered off. Likewise, when one of the two components (pump 209 or vacuum controller 213) is powered on, the other is also automatically powered on.
With the basic structure of the aspiration system 201 being thusly disclosed, a greater appreciation of the construction and benefits of may be gained from the following discussion of the operation of the aspiration system 201 as shown in the flow chart at
In some example methods, activating a vacuum pump comprises activating the vacuum pump at full power, as shown in
The vacuum is imposed on the catheter 203 through the receptacle 205. The catheter 203 draws fluid from the patient. The flow is measured and a closed circuit loop is formed that provides controlling the desired flow with the amount of vacuum. When the flow drops below the lower limit, the vacuum controller 213 returns the vacuum pump 209 to full power and commands the regulator to fully close the system to atmospheric pressure.
For example,
Adjusting the vacuum pressure can be accomplished by decreasing the vacuum pressure upon a determination that the flow parameter is above an upper limit of the target range. In some examples, the upper limit is a flow rate of from 70 mL per minute to 130 mL per minute (including, for example, 70 mL per minute, 75 mL per minute, 80 mL per minute, 85 mL per minute, 90 mL per minute, 95 mL per minute, 100 mL per minute, 105 mL per minute, 110 mL per minute, 115 mL per minute, 120 mL per minute, 125 mL per minute, and 130 mL per minute).
In some example methods, the vacuum pressure is decreased until the measured flow parameter reaches an intermediate level flow rate of from 20 mL per minute to 50 mL per minute (including, for example, 20 mL per minute, 25 mL per minute, 30 mL per minute, 35 mL per minute, 40 mL per minute, 45 mL per minute, and 50 mL per minute).
Adjusting the vacuum pressure can be accomplished by increasing the vacuum pressure upon a determination that the flow parameter is below a lower limit of the target range. The lower limit can be, for example, from 0 mL per minute to 50 mL per minute (including, for example, 0 mL per minute, 10 mL per minute, 15 mL per minute, 20 mL per minute, 25 mL per minute, 30 mL per minute, 35 mL per minute, 40 mL per minute, 45 mL per minute, and 50 mL per minute).
In some implementations, decreasing or increasing the vacuum pressure can occur gradually, or in a stepwise manner, according to an aspiration program. This helps to reduce sudden surges and stops, giving the practitioner sufficient time to respond as necessary to sudden changes in flow rate. For example,
In some implementations, the durations of time in each of the steps of the aspiration program shown in
It should be appreciated that the logical operations described herein with respect to the various figures may be implemented (1) as a sequence of computer implemented acts or program modules (i.e., software) running on a computing device (e.g., the computing device described in
Referring to
In an implementation, the computing device 900 may comprise two or more computers in communication with each other that collaborate to perform a task. For example, but not by way of limitation, an application may be partitioned in such a way as to permit concurrent and/or parallel processing of the instructions of the application. Alternatively, the data processed by the application may be partitioned in such a way as to permit concurrent and/or parallel processing of different portions of a data set by the two or more computers. In an implementation, virtualization software may be employed by the computing device 900 to provide the functionality of a number of servers that is not directly bound to the number of computers in the computing device 900. For example, virtualization software may provide twenty virtual servers on four physical computers. In an implementation, the functionality disclosed above may be provided by executing the application and/or applications in a cloud computing environment. Cloud computing may comprise providing computing services via a network connection using dynamically scalable computing resources. Cloud computing may be supported, at least in part, by virtualization software. A cloud computing environment may be established by an enterprise and/or may be hired on an as-needed basis from a third party provider. Some cloud computing environments may comprise cloud computing resources owned and operated by the enterprise as well as cloud computing resources hired and/or leased from a third party provider.
In its most basic configuration, computing device 900 typically includes at least one processing unit 920 and system memory 930. Depending on the exact configuration and type of computing device, system memory 930 may be volatile (such as random access memory (RAM)), non-volatile (such as read-only memory (ROM), flash memory, etc.), or some combination of the two. This most basic configuration is illustrated in
Computing device 900 may have additional features/functionality. For example, computing device 900 may include additional storage such as removable storage 940 and non-removable storage 950 including, but not limited to, magnetic or optical disks or tapes. Computing device 900 may also contain network connection(s) 980 that allow the device to communicate with other devices such as over the communication pathways described herein. The network connection(s) 980 may take the form of modems, modem banks, Ethernet cards, universal serial bus (USB) interface cards, serial interfaces, token ring cards, fiber distributed data interface (FDDI) cards, wireless local area network (WLAN) cards, radio transceiver cards such as code division multiple access (CDMA), global system for mobile communications (GSM), long-term evolution (LTE), worldwide interoperability for microwave access (WiMAX), and/or other air interface protocol radio transceiver cards, and other well-known network devices. Computing device 900 may also have input device(s) 970 such as a keyboards, keypads, switches, dials, mice, track balls, touch screens, voice recognizers, card readers, paper tape readers, or other well-known input devices. Output device(s) 960 such as a printers, video monitors, liquid crystal displays (LCDs), touch screen displays, displays, speakers, etc. may also be included. The additional devices may be connected to the bus in order to facilitate communication of data among the components of the computing device 900. All these devices are well known in the art and need not be discussed at length here.
The processing unit 920 may be configured to execute program code encoded in tangible, computer-readable media. Tangible, computer-readable media refers to any media that is capable of providing data that causes the computing device 900 (i.e., a machine) to operate in a particular fashion. Various computer-readable media may be utilized to provide instructions to the processing unit 920 for execution. Example tangible, computer-readable media may include, but is not limited to, volatile media, non-volatile media, removable media and non-removable media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data. System memory 930, removable storage 940, and non-removable storage 950 are all examples of tangible, computer storage media. Example tangible, computer-readable recording media include, but are not limited to, an integrated circuit (e.g., field-programmable gate array or application-specific IC), a hard disk, an optical disk, a magneto-optical disk, a floppy disk, a magnetic tape, a holographic storage medium, a solid-state device, RAM, ROM, electrically erasable program read-only memory (EEPROM), flash memory or other memory technology, CD-ROM, digital versatile disks (DVD) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices.
It is fundamental to the electrical engineering and software engineering arts that functionality that can be implemented by loading executable software into a computer can be converted to a hardware implementation by well-known design rules. Decisions between implementing a concept in software versus hardware typically hinge on considerations of stability of the design and numbers of units to be produced rather than any issues involved in translating from the software domain to the hardware domain. Generally, a design that is still subject to frequent change may be preferred to be implemented in software, because re-spinning a hardware implementation is more expensive than re-spinning a software design. Generally, a design that is stable that will be produced in large volume may be preferred to be implemented in hardware, for example in an application specific integrated circuit (ASIC), because for large production runs the hardware implementation may be less expensive than the software implementation. Often a design may be developed and tested in a software form and later transformed, by well-known design rules, to an equivalent hardware implementation in an application specific integrated circuit that hardwires the instructions of the software. In the same manner as a machine controlled by a new ASIC is a particular machine or apparatus, likewise a computer that has been programmed and/or loaded with executable instructions may be viewed as a particular machine or apparatus.
In an example implementation, the processing unit 920 may execute program code stored in the system memory 930. For example, the bus may carry data to the system memory 930, from which the processing unit 920 receives and executes instructions. The data received by the system memory 930 may optionally be stored on the removable storage 940 or the non-removable storage 950 before or after execution by the processing unit 920.
It should be understood that the various techniques described herein may be implemented in connection with hardware or software or, where appropriate, with a combination thereof. Thus, the methods and apparatuses of the presently disclosed subject matter, or certain aspects or portions thereof, may take the form of program code (i.e., instructions) embodied in tangible media, such as floppy diskettes, CD-ROMs, hard drives, or any other machine-readable storage medium wherein, when the program code is loaded into and executed by a machine, such as a computing device, the machine becomes an apparatus for practicing the presently disclosed subject matter. In the case of program code execution on programmable computers, the computing device generally includes a processor, a storage medium readable by the processor (including volatile and non-volatile memory and/or storage elements), at least one input device, and at least one output device. One or more programs may implement or utilize the processes described in connection with the presently disclosed subject matter, e.g., through the use of an application programming interface (API), reusable controls, or the like. Such programs may be implemented in a high level procedural or object-oriented programming language to communicate with a computer system. However, the program(s) can be implemented in assembly or machine language, if desired. In any case, the language may be a compiled or interpreted language and it may be combined with hardware implementations.
Implementations of the methods and systems may be described herein with reference to block diagrams and flowchart illustrations of methods, systems, apparatuses and computer program products. It will be understood that each block of the block diagrams and flowchart illustrations, and combinations of blocks in the block diagrams and flowchart illustrations, respectively, can be implemented by computer program instructions. These computer program instructions may be loaded onto a general purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine, such that the instructions which execute on the computer or other programmable data processing apparatus create a means for implementing the functions specified in the flowchart block or blocks.
These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including computer-readable instructions for implementing the function specified in the flowchart block or blocks. The computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer-implemented process such that the instructions that execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart block or blocks.
Accordingly, blocks of the block diagrams and flowchart illustrations support combinations of means for performing the specified functions, combinations of steps for performing the specified functions and program instruction means for performing the specified functions. It will also be understood that each block of the block diagrams and flowchart illustrations, and combinations of blocks in the block diagrams and flowchart illustrations, can be implemented by special purpose hardware-based computer systems that perform the specified functions or steps, or combinations of special purpose hardware and computer instructions.
Conventional aspiration systems operate with the vacuum being controlled with a “foot valve” by the operating physician. This is not very precise and is a distraction to the primary job of guiding the catheter. The principle of this system is to automate the process. The reader is directed to the flow chart of
The system is controlled by a microprocessor controller (MC). A simple device as compared to a conventional computer and can run “stand alone”. That means all it needs to run is powering it up. The program is written to be failsafe and straightforward. On power up the MC initializes and performs a test of the system and a checksum on the program. Any problem with this stops the process. The system uses a Vacuum Regulator (VR) module. It takes raw unregulated vacuum from a user supplied vacuum pump (VP). The VR can be set to deliver from full to almost zero vacuum buy the MC while the VP is set to maximum vacuum.
Another component of the system is the Flow Sensor (FS). This device measures the amount of blood flow out of the catheter. There are several available technologies for the sensor. The most straight forward and inexpensive is the impeller rotational sensor. It measures the flow by how fast an impeller spins.
An ultrasonic flow sensor works well in this application and can accurately measure the low flow rates that might indicate the possibility of a blockage caused by a blood. A small tube from the catheter is placed in a cavity on the sensor and the velocity of the flow is determined. An electrical pulse train is produced that has a frequency proportional to the flow rate that is read by the MC. The sensor is completely isolated from any liquids and can be used repeatedly, where as the rotational sensor would have to be disposed of after every procedure.
In this example, 100 mL/minute is the upper limit on the flow rate. After power on test is complete, the VR commands full vacuum. The flow can reach 100 m/min quickly, and the MC detects that and quickly commands the VR to reduce vacuum and to control the flow by adjusting the vacuum to a midline flow rate of around 30 m/min. Without the VR, blood flow out of the catheter would be excessive.
The flow rate from 100 m/min to 30 mL/min can be achieved in steps so that the clinician gets enough time to make necessary decisions/actions. Same delay time or stepped approach is taken for the application of full vacuum to the aspiration tubing when the flow rate falls below a lower limit of 10 ml/min (or the tip of the catheter engages a clot, in practice).
If, while the system is regulating to 30 m/min, it drops below 10 m/min, a blockage of the catheter has probably occurred. The system will attempt to “Clear” the blockage, usually caused by encountering a blood clot, by commanding full vacuum power from the VR. As in the beginning, when the flow hits 100 m/min, the MC will command the VR will scale back and regulate to 30 mL/min.
The cycle repeats until the unit is shut off. Before complete shutdown, the MC commands the VR to completely release the vacuum.
The corresponding structures, materials, acts, and equivalents of all means or step plus function elements in the claims below are intended to include any structure, material, or act for performing the function in combination with other claimed elements as specifically claimed. The description of the present invention has been presented for purposes of illustration and description, but is not intended to be exhaustive or limited to the invention in the form disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the invention. The implementation was chosen and described in order to best explain the principles of the invention and the practical application, and to enable others of ordinary skill in the art to understand the invention for various implementations with various modifications as are suited to the particular use contemplated.
This application is a continuation of U.S. patent application Ser. No. 17/726,791, filed Apr. 22, 2022, which claims the benefit of U.S. Provisional Application 63/180,291, filed Apr. 27, 2021. Each of the aforementioned applications is incorporated herein by reference in its entirety for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
3693613 | Kelman | Sep 1972 | A |
3930505 | Wallach | Jan 1976 | A |
4244230 | Bauer | Jan 1981 | A |
4332560 | Rait | Jun 1982 | A |
4460361 | Nichols | Jul 1984 | A |
4654029 | D'Antonio | Mar 1987 | A |
4735606 | Davidson | Apr 1988 | A |
4935005 | Haines | Jun 1990 | A |
5094961 | DelValle et al. | Mar 1992 | A |
5195995 | Walker | Mar 1993 | A |
5201703 | Gentelia | Apr 1993 | A |
5242404 | Conley et al. | Sep 1993 | A |
5536242 | Willard | Jul 1996 | A |
5606968 | Mang | Mar 1997 | A |
5897524 | Wortrich et al. | Apr 1999 | A |
5941869 | Patterson | Aug 1999 | A |
6013046 | Maaskamp et al. | Jan 2000 | A |
6039715 | Mackool | Mar 2000 | A |
6055458 | Cochran et al. | Apr 2000 | A |
6258053 | Mackool | Jul 2001 | B1 |
6290689 | Delaney et al. | Sep 2001 | B1 |
6319223 | Wortrich et al. | Nov 2001 | B1 |
6514268 | Finlay et al. | Feb 2003 | B2 |
6629646 | Ivri | Oct 2003 | B1 |
6663613 | Evans et al. | Dec 2003 | B1 |
6730063 | Delaney et al. | May 2004 | B2 |
6773445 | Finlay et al. | Aug 2004 | B2 |
6790196 | Kokate et al. | Sep 2004 | B2 |
6887220 | Kataishi et al. | May 2005 | B2 |
6926208 | Ivri | Aug 2005 | B2 |
6929633 | Evans et al. | Aug 2005 | B2 |
6979293 | Hansmann et al. | Dec 2005 | B2 |
7004931 | Hogendijk | Feb 2006 | B2 |
7108197 | Ivri | Sep 2006 | B2 |
7141045 | Johansson et al. | Nov 2006 | B2 |
7160268 | Darnell et al. | Jan 2007 | B2 |
7244250 | Miki et al. | Jul 2007 | B2 |
7250042 | Rauker et al. | Jul 2007 | B2 |
7276052 | Kobayashi et al. | Oct 2007 | B2 |
7276060 | Madden | Oct 2007 | B2 |
7309334 | von Hoffmann | Dec 2007 | B2 |
7422579 | Wahr | Sep 2008 | B2 |
7491192 | Di Fiore | Feb 2009 | B2 |
7608063 | Le et al. | Oct 2009 | B2 |
7655016 | Demarais et al. | Feb 2010 | B2 |
7666161 | Nash et al. | Feb 2010 | B2 |
7674272 | Torrance et al. | Mar 2010 | B2 |
7713231 | Wulfman et al. | May 2010 | B2 |
7713235 | Torrance et al. | May 2010 | B2 |
7717934 | Knsleika | May 2010 | B2 |
7736355 | Itou et al. | Jun 2010 | B2 |
7762995 | Eversull et al. | Jul 2010 | B2 |
7763010 | Evans et al. | Jul 2010 | B2 |
7780694 | Palmer et al. | Aug 2010 | B2 |
7792647 | Ding et al. | Sep 2010 | B1 |
7842009 | Torrance et al. | Nov 2010 | B2 |
7842010 | Bonnette et al. | Nov 2010 | B2 |
7887510 | Karpowicz | Feb 2011 | B2 |
7918822 | Kumar et al. | Apr 2011 | B2 |
7931659 | Bose et al. | Apr 2011 | B2 |
7935077 | Thor et al. | May 2011 | B2 |
7938820 | Webster et al. | May 2011 | B2 |
7942852 | Mas et al. | May 2011 | B2 |
7947012 | Spurchise et al. | May 2011 | B2 |
7959608 | Nash et al. | Jun 2011 | B2 |
7976528 | Nash et al. | Jul 2011 | B2 |
7981128 | To et al. | Jul 2011 | B2 |
7998104 | Chang | Aug 2011 | B2 |
8002728 | Chang | Aug 2011 | B2 |
8007506 | To et al. | Aug 2011 | B2 |
8012117 | Bonnette et al. | Sep 2011 | B2 |
8021351 | Boldenow et al. | Sep 2011 | B2 |
8052640 | Fiorella et al. | Nov 2011 | B2 |
8057439 | Di Fiore | Nov 2011 | B2 |
8066677 | Lnnn et al. | Nov 2011 | B2 |
8066757 | Ferrera et al. | Nov 2011 | B2 |
8070694 | Galdonik et al. | Dec 2011 | B2 |
8070762 | Escudero et al. | Dec 2011 | B2 |
8070791 | Ferrera et al. | Dec 2011 | B2 |
8088103 | Teeslink et al. | Jan 2012 | B2 |
8088140 | Ferrera et al. | Jan 2012 | B2 |
8114106 | Straub | Feb 2012 | B2 |
8137377 | Palmer et al. | Mar 2012 | B2 |
8142442 | Palmer et al. | Mar 2012 | B2 |
8157760 | Criado et al. | Apr 2012 | B2 |
8162878 | Bonnette et al. | Apr 2012 | B2 |
8231600 | von Hoffmann | Jul 2012 | B2 |
8252020 | Hauser et al. | Aug 2012 | B2 |
8262611 | Teeslink et al. | Sep 2012 | B2 |
8298210 | Provost-Tine et al. | Oct 2012 | B2 |
8303538 | Bonnette et al. | Nov 2012 | B2 |
8317748 | Fiorella et al. | Nov 2012 | B2 |
8323240 | Wulfman et al. | Dec 2012 | B2 |
8337516 | Escudero et al. | Dec 2012 | B2 |
8361105 | Adams et al. | Jan 2013 | B2 |
8366663 | Fiorella et al. | Feb 2013 | B2 |
8366735 | Bose et al. | Feb 2013 | B2 |
8388582 | Enbanks et al. | Mar 2013 | B2 |
8388628 | Eversull et al. | Mar 2013 | B2 |
8398589 | Teeslink et al. | Mar 2013 | B2 |
8405568 | Knudsen et al. | Mar 2013 | B2 |
8430837 | Jenson et al. | Apr 2013 | B2 |
8430840 | Nazarifar et al. | Apr 2013 | B2 |
8435228 | Wulfman et al. | May 2013 | B2 |
8439878 | Bonnette et al. | May 2013 | B2 |
8444661 | Nair et al. | May 2013 | B2 |
8460312 | Bose et al. | Jun 2013 | B2 |
8465467 | Gao | Jun 2013 | B2 |
8469970 | Diamant et al. | Jun 2013 | B2 |
8475484 | Wulfman et al. | Jul 2013 | B2 |
8500683 | Constantz et al. | Aug 2013 | B2 |
8529491 | Beiriger | Sep 2013 | B2 |
8535290 | Evans et al. | Sep 2013 | B2 |
8545432 | Renati et al. | Oct 2013 | B2 |
8545514 | Ferrera | Oct 2013 | B2 |
8562555 | MacMahon et al. | Oct 2013 | B2 |
8568432 | Straub | Oct 2013 | B2 |
8574262 | Ferrera et al. | Nov 2013 | B2 |
8585713 | Ferrera et al. | Nov 2013 | B2 |
8591453 | Stubkjaer et al. | Nov 2013 | B2 |
8628549 | To et al. | Jan 2014 | B2 |
8647355 | Escudero et al. | Feb 2014 | B2 |
8652086 | Gerg et al. | Feb 2014 | B2 |
8657785 | Torrance et al. | Feb 2014 | B2 |
8668665 | Gerg et al. | Mar 2014 | B2 |
8679142 | Slee et al. | Mar 2014 | B2 |
8679150 | Janardhan et al. | Mar 2014 | B1 |
8690907 | Janardhan et al. | Apr 2014 | B1 |
8696622 | Fiorella et al. | Apr 2014 | B2 |
8702652 | Fiorella et al. | Apr 2014 | B2 |
8715220 | Gerg et al. | May 2014 | B2 |
8715314 | Janardhan et al. | May 2014 | B1 |
8715315 | Janardhan et al. | May 2014 | B1 |
8715316 | Janardhan et al. | May 2014 | B1 |
8715317 | Janardhan et al. | May 2014 | B1 |
8721676 | Janardhan et al. | May 2014 | B1 |
8721677 | Janardhan et al. | May 2014 | B1 |
8728116 | Janardhan et al. | May 2014 | B1 |
8728117 | Janardhan et al. | May 2014 | B1 |
8733618 | Janardhan et al. | May 2014 | B1 |
8735777 | Janardhan et al. | May 2014 | B1 |
8747432 | Janardhan et al. | Jun 2014 | B1 |
8753371 | Janardhan et al. | Jun 2014 | B1 |
8758325 | Webster et al. | Jun 2014 | B2 |
8764724 | Itou et al. | Jul 2014 | B2 |
8783151 | Janardhan et al. | Jul 2014 | B1 |
8784355 | Criado et al. | Jul 2014 | B2 |
8784434 | Rosenbluth et al. | Jul 2014 | B2 |
8784446 | Janardhan et al. | Jul 2014 | B1 |
8789452 | Janardhan et al. | Jul 2014 | B1 |
8790365 | Janardhan et al. | Jul 2014 | B1 |
8795330 | Janardhan et al. | Aug 2014 | B1 |
8801749 | Adams et al. | Aug 2014 | B2 |
8803030 | Janardhan et al. | Aug 2014 | B1 |
8813625 | Janardhan et al. | Aug 2014 | B1 |
8814892 | Galdonik et al. | Aug 2014 | B2 |
8816247 | Janardhan et al. | Aug 2014 | B1 |
8828045 | Janardhan et al. | Sep 2014 | B1 |
8845678 | Janardhan et al. | Sep 2014 | B1 |
8845679 | Janardhan et al. | Sep 2014 | B1 |
8852219 | Wulfman et al. | Oct 2014 | B2 |
8852227 | Janardhan et al. | Oct 2014 | B1 |
8859934 | Janardhan et al. | Oct 2014 | B1 |
8863631 | Janardhan et al. | Oct 2014 | B1 |
8866049 | Janardhan et al. | Oct 2014 | B1 |
8869670 | Janardhan et al. | Oct 2014 | B1 |
8870805 | Chang | Oct 2014 | B2 |
8870824 | Kusakabe | Oct 2014 | B2 |
8870901 | Janardhan et al. | Oct 2014 | B1 |
8870910 | Janardhan et al. | Oct 2014 | B1 |
8872068 | Janardhan et al. | Oct 2014 | B1 |
8882797 | Janardhan et al. | Nov 2014 | B2 |
8888801 | To et al. | Nov 2014 | B2 |
8895891 | Janardhan et al. | Nov 2014 | B2 |
8900179 | Jenson et al. | Dec 2014 | B2 |
8900257 | Straub et al. | Dec 2014 | B2 |
8904914 | Janardhan et al. | Dec 2014 | B2 |
8910555 | Janardhan et al. | Dec 2014 | B2 |
8920402 | Nash et al. | Dec 2014 | B2 |
8920448 | To et al. | Dec 2014 | B2 |
8926680 | Ferrera et al. | Jan 2015 | B2 |
8932320 | Janardhan et al. | Jan 2015 | B1 |
8932321 | Janardhan et al. | Jan 2015 | B1 |
8939931 | von Hoffmann | Jan 2015 | B2 |
8940003 | Slee et al. | Jan 2015 | B2 |
8945143 | Ferrera et al. | Feb 2015 | B2 |
8945172 | Ferrera et al. | Feb 2015 | B2 |
8951224 | Wulfman et al. | Feb 2015 | B2 |
8956386 | Hauser et al. | Feb 2015 | B2 |
8970384 | Yodfat et al. | Mar 2015 | B2 |
8986241 | Evans et al. | Mar 2015 | B2 |
8998843 | Bonnette et al. | Apr 2015 | B2 |
9011364 | Criado et al. | Apr 2015 | B2 |
9011467 | Garrison et al. | Apr 2015 | B2 |
9017309 | Tanikawa et al. | Apr 2015 | B2 |
9039715 | Diamant et al. | May 2015 | B2 |
9050127 | Bonnette et al. | Jun 2015 | B2 |
9055951 | Deshpande | Jun 2015 | B2 |
9055963 | Henkes et al. | Jun 2015 | B2 |
9072540 | Jarnagin et al. | Jul 2015 | B2 |
9078682 | Lenker et al. | Jul 2015 | B2 |
9095371 | Escudero et al. | Aug 2015 | B2 |
9113936 | Look et al. | Aug 2015 | B2 |
9119656 | Leynov et al. | Sep 2015 | B2 |
9125728 | Angel et al. | Sep 2015 | B2 |
9126018 | Garrison | Sep 2015 | B1 |
9138527 | Renati et al. | Sep 2015 | B2 |
9149568 | Gerg et al. | Oct 2015 | B2 |
9161765 | Thor et al. | Oct 2015 | B2 |
9161766 | Slee et al. | Oct 2015 | B2 |
9179909 | Garrison et al. | Nov 2015 | B2 |
9179931 | Janardhan et al. | Nov 2015 | B2 |
9179995 | Janardhan et al. | Nov 2015 | B2 |
9186487 | Dubrul et al. | Nov 2015 | B2 |
9198679 | To et al. | Dec 2015 | B2 |
9198687 | Fulkerson et al. | Dec 2015 | B2 |
9220522 | Fulkerson et al. | Dec 2015 | B2 |
9238122 | Malhi et al. | Jan 2016 | B2 |
9239049 | Jarnagin et al. | Jan 2016 | B2 |
9241699 | Kume et al. | Jan 2016 | B1 |
9248221 | Look et al. | Feb 2016 | B2 |
9259215 | Chou et al. | Feb 2016 | B2 |
9259237 | Quick et al. | Feb 2016 | B2 |
9265512 | Garrison et al. | Feb 2016 | B2 |
9282989 | Boukhny et al. | Mar 2016 | B2 |
9283040 | Hendrick | Mar 2016 | B2 |
9295373 | Torrance et al. | Mar 2016 | B2 |
9301829 | Rauker et al. | Apr 2016 | B2 |
9308016 | Escudero et al. | Apr 2016 | B2 |
9308315 | Stubkjaer et al. | Apr 2016 | B2 |
9314263 | Escudero et al. | Apr 2016 | B2 |
9314324 | Janardhan et al. | Apr 2016 | B2 |
9320532 | Ferrera et al. | Apr 2016 | B2 |
9332998 | Ray et al. | May 2016 | B2 |
9332999 | Ray et al. | May 2016 | B2 |
9333007 | Escudero et al. | May 2016 | B2 |
9375223 | Wallace | Jun 2016 | B2 |
9387098 | Ferrera et al. | Jul 2016 | B2 |
9399118 | Kume et al. | Jul 2016 | B2 |
9408620 | Rosenbluth et al. | Aug 2016 | B2 |
9408626 | Tekulve | Aug 2016 | B2 |
9408964 | Breiter et al. | Aug 2016 | B2 |
9421080 | Angel et al. | Aug 2016 | B2 |
9427300 | Angel et al. | Aug 2016 | B2 |
9433427 | Look et al. | Sep 2016 | B2 |
9445828 | Turjman et al. | Sep 2016 | B2 |
9445943 | Wilson et al. | Sep 2016 | B2 |
9463035 | Greenhalgh et al. | Oct 2016 | B1 |
9492192 | To et al. | Nov 2016 | B2 |
9492637 | Garrison et al. | Nov 2016 | B2 |
9498604 | Dubrul et al. | Nov 2016 | B2 |
9510854 | Mallaby | Dec 2016 | B2 |
9522258 | Tekulve | Dec 2016 | B2 |
9526504 | Chang | Dec 2016 | B2 |
9526864 | Quick | Dec 2016 | B2 |
9526865 | Quick | Dec 2016 | B2 |
9526874 | Teeslink et al. | Dec 2016 | B2 |
9526922 | Hossack et al. | Dec 2016 | B2 |
9532792 | Galdonik et al. | Jan 2017 | B2 |
9539022 | Bowman | Jan 2017 | B2 |
9549850 | Sorensen et al. | Jan 2017 | B2 |
9554822 | Consigny | Jan 2017 | B2 |
9561345 | Garrison et al. | Feb 2017 | B2 |
9592068 | Janardhan et al. | Mar 2017 | B2 |
9597101 | Galdonik et al. | Mar 2017 | B2 |
9629654 | Andersen | Apr 2017 | B2 |
9649437 | Eubanks et al. | May 2017 | B2 |
9655633 | Leynov et al. | May 2017 | B2 |
9655755 | Chou et al. | May 2017 | B2 |
9656043 | Bhagchandani et al. | May 2017 | B2 |
9662118 | Chang | May 2017 | B2 |
9662129 | Galdonik et al. | May 2017 | B2 |
9662137 | Jenson et al. | May 2017 | B2 |
9662480 | Kume et al. | May 2017 | B2 |
9668767 | To et al. | Jun 2017 | B2 |
9669191 | Chou et al. | Jun 2017 | B2 |
9675376 | To et al. | Jun 2017 | B2 |
9681882 | Garrison et al. | Jun 2017 | B2 |
9693898 | Farley et al. | Jul 2017 | B2 |
9700332 | Marchand et al. | Jul 2017 | B2 |
9700347 | Shiber | Jul 2017 | B2 |
9707002 | Henkes et al. | Jul 2017 | B2 |
9717519 | Rosenbluth et al. | Aug 2017 | B2 |
9731065 | Bourne et al. | Aug 2017 | B2 |
9737328 | Bonnette et al. | Aug 2017 | B2 |
9750517 | Agrawal | Sep 2017 | B2 |
9750524 | Janardhan et al. | Sep 2017 | B2 |
9775964 | Eubanks et al. | Oct 2017 | B2 |
9789242 | Criado et al. | Oct 2017 | B2 |
9801642 | Thor et al. | Oct 2017 | B2 |
9801643 | Hansen et al. | Oct 2017 | B2 |
9801644 | Ulm, III | Oct 2017 | B2 |
9808266 | Ray et al. | Nov 2017 | B2 |
9808271 | Ulm, III | Nov 2017 | B2 |
9808277 | Nash et al. | Nov 2017 | B2 |
9814478 | Ulm, III | Nov 2017 | B2 |
9820761 | Garrison et al. | Nov 2017 | B2 |
9820764 | Ulm, III | Nov 2017 | B2 |
9826998 | Ulm, III | Nov 2017 | B2 |
9833251 | Janardhan et al. | Dec 2017 | B2 |
9833253 | Ulm, III | Dec 2017 | B1 |
9833257 | Bonnette et al. | Dec 2017 | B2 |
9833555 | Criado et al. | Dec 2017 | B2 |
9839506 | Ulm, III | Dec 2017 | B2 |
9839771 | Eversull et al. | Dec 2017 | B2 |
9844387 | Marchand et al. | Dec 2017 | B2 |
9848881 | Sutton et al. | Dec 2017 | B2 |
9848975 | Nash et al. | Dec 2017 | B2 |
9855375 | Charron et al. | Jan 2018 | B2 |
9861783 | Garrison et al. | Jan 2018 | B2 |
9878076 | Gulcher et al. | Jan 2018 | B2 |
9883877 | Look et al. | Feb 2018 | B2 |
9895158 | Dixon et al. | Feb 2018 | B2 |
9895473 | Look et al. | Feb 2018 | B2 |
9901435 | Janardhan et al. | Feb 2018 | B2 |
9907567 | Shiber | Mar 2018 | B2 |
9913936 | Look et al. | Mar 2018 | B2 |
9925315 | Eubanks et al. | Mar 2018 | B2 |
9931166 | Sauro et al. | Apr 2018 | B2 |
9931447 | Layser et al. | Apr 2018 | B2 |
9943321 | Nita | Apr 2018 | B2 |
9943668 | Jahrmarkt | Apr 2018 | B2 |
9955987 | Ulm, III | May 2018 | B2 |
9962177 | Ulm, III | May 2018 | B2 |
9962288 | Yalamanehili | May 2018 | B2 |
9987028 | Lowinger et al. | Jun 2018 | B2 |
10004531 | Rosenbluth et al. | Jun 2018 | B2 |
10010657 | Torrance et al. | Jul 2018 | B2 |
10016211 | Ferrera et al. | Jul 2018 | B2 |
10016266 | Hauser | Jul 2018 | B2 |
10022139 | Kobayashi et al. | Jul 2018 | B2 |
10039906 | Kume et al. | Aug 2018 | B2 |
10045790 | Cox et al. | Aug 2018 | B2 |
10058339 | Galdonik et al. | Aug 2018 | B2 |
10064643 | Malhi et al. | Sep 2018 | B2 |
10085864 | Chou et al. | Oct 2018 | B2 |
10098651 | Marchand et al. | Oct 2018 | B2 |
10098724 | Adams et al. | Oct 2018 | B2 |
10117669 | Kobayashi et al. | Nov 2018 | B2 |
10117670 | Kobayashi et al. | Nov 2018 | B2 |
10137034 | Heeren | Nov 2018 | B2 |
10143489 | Kobayashi et al. | Dec 2018 | B2 |
10149692 | Turjman et al. | Dec 2018 | B2 |
10149698 | Wulfman et al. | Dec 2018 | B2 |
10154853 | To et al. | Dec 2018 | B2 |
10154854 | To et al. | Dec 2018 | B2 |
10179224 | Yang et al. | Jan 2019 | B2 |
10182940 | Chandrakant et al. | Jan 2019 | B2 |
10183145 | Yang et al. | Jan 2019 | B2 |
10183146 | Yang et al. | Jan 2019 | B2 |
10183147 | Yang et al. | Jan 2019 | B2 |
10188399 | Chang | Jan 2019 | B2 |
10188409 | Smalling | Jan 2019 | B2 |
10192230 | Look et al. | Jan 2019 | B2 |
10201359 | Fiorella et al. | Feb 2019 | B2 |
10213582 | Garrison et al. | Feb 2019 | B2 |
10219814 | Feltyberger et al. | Mar 2019 | B2 |
10226263 | Look et al. | Mar 2019 | B2 |
10226268 | Ulm, III | Mar 2019 | B2 |
10226275 | Eseudero et al. | Mar 2019 | B2 |
10226563 | Garrison et al. | Mar 2019 | B2 |
10226598 | Chou et al. | Mar 2019 | B2 |
10238406 | Cox et al. | Mar 2019 | B2 |
10238853 | Kume et al. | Mar 2019 | B2 |
10251739 | Janardhan et al. | Apr 2019 | B2 |
10258358 | Ulm, III | Apr 2019 | B2 |
10271864 | Greenhalgh et al. | Apr 2019 | B2 |
D847864 | Janardhan et al. | May 2019 | S |
D847865 | Janardhan et al. | May 2019 | S |
D847866 | Janardhan et al. | May 2019 | S |
10278719 | Ulm, III | May 2019 | B2 |
10278861 | Bourne et al. | May 2019 | B2 |
10285720 | Gilvarry et al. | May 2019 | B2 |
10299824 | Walzman | May 2019 | B2 |
D850490 | Janardhan et al. | Jun 2019 | S |
10307242 | Walzman | Jun 2019 | B2 |
10314608 | Jenson et al. | Jun 2019 | B2 |
10314609 | Bonnette et al. | Jun 2019 | B2 |
10314684 | Walzman | Jun 2019 | B2 |
10314953 | Ovehinnikov et al. | Jun 2019 | B2 |
10321925 | Ulm, III | Jun 2019 | B2 |
10327790 | Garrison et al. | Jun 2019 | B2 |
10335186 | Rosenbluth et al. | Jul 2019 | B2 |
10335260 | Janardhan et al. | Jul 2019 | B2 |
10342571 | Marchand et al. | Jul 2019 | B2 |
10342655 | Janardhan et al. | Jul 2019 | B2 |
10349960 | Quick | Jul 2019 | B2 |
10357242 | Garrison et al. | Jul 2019 | B2 |
10357266 | Ulm, III | Jul 2019 | B2 |
10363054 | Vale et al. | Jul 2019 | B2 |
10369270 | Stubkjaer et al. | Aug 2019 | B2 |
10369346 | Ryan et al. | Aug 2019 | B2 |
10376678 | Levine | Aug 2019 | B2 |
10376685 | Angel et al. | Aug 2019 | B2 |
10383644 | Molaei et al. | Aug 2019 | B2 |
10384034 | Garrison et al. | Aug 2019 | B2 |
10390926 | Janardhan et al. | Aug 2019 | B2 |
10398595 | Zacharias | Sep 2019 | B2 |
10405924 | Bowe | Sep 2019 | B2 |
10413310 | Ferrera et al. | Sep 2019 | B2 |
10420572 | Ulm, III | Sep 2019 | B2 |
10426511 | Hehrlein | Oct 2019 | B2 |
10426885 | Criado et al. | Oct 2019 | B2 |
10441301 | Vale et al. | Oct 2019 | B2 |
10441745 | Yang et al. | Oct 2019 | B2 |
10448969 | Sutton et al. | Oct 2019 | B2 |
10456151 | Slee et al. | Oct 2019 | B2 |
10456555 | Garrison et al. | Oct 2019 | B2 |
10463351 | Merk et al. | Nov 2019 | B2 |
10463386 | Ogle et al. | Nov 2019 | B2 |
10463468 | Janardhan et al. | Nov 2019 | B2 |
10470926 | Zacharias | Nov 2019 | B2 |
10471233 | Garrison et al. | Nov 2019 | B2 |
10485551 | Turjman et al. | Nov 2019 | B2 |
10485564 | Goyal | Nov 2019 | B2 |
10485565 | Galdonik et al. | Nov 2019 | B2 |
10485952 | Garrison et al. | Nov 2019 | B2 |
10492805 | Culbert et al. | Dec 2019 | B2 |
10492809 | Ulm, III | Dec 2019 | B2 |
10499944 | Mallaby | Dec 2019 | B2 |
10517633 | Nash et al. | Dec 2019 | B2 |
10524811 | Marchand et al. | Jan 2020 | B2 |
10531882 | Anand et al. | Jan 2020 | B2 |
10531883 | DeVille et al. | Jan 2020 | B1 |
10537471 | Look et al. | Jan 2020 | B2 |
10561440 | Look et al. | Feb 2020 | B2 |
10569049 | Garrison et al. | Feb 2020 | B2 |
10588655 | Rosenbluth et al. | Mar 2020 | B2 |
10588656 | Trosper et al. | Mar 2020 | B2 |
10595818 | Levine | Mar 2020 | B2 |
10603415 | Look et al. | Mar 2020 | B2 |
10610256 | Bowman | Apr 2020 | B2 |
10617435 | Vale et al. | Apr 2020 | B2 |
10617562 | Bourne et al. | Apr 2020 | B2 |
10624659 | Gamba et al. | Apr 2020 | B2 |
10632245 | Enbanks et al. | Apr 2020 | B2 |
10646239 | Garrison et al. | May 2020 | B2 |
10653434 | Yang et al. | May 2020 | B1 |
10661053 | Yang et al. | May 2020 | B2 |
10682152 | Vale et al. | Jun 2020 | B2 |
10690127 | Ochoa | Jun 2020 | B2 |
10695159 | Hauser | Jun 2020 | B2 |
10702292 | Look et al. | Jul 2020 | B2 |
10702415 | Charles | Jul 2020 | B2 |
10702634 | Luxon et al. | Jul 2020 | B2 |
10709466 | Bowman et al. | Jul 2020 | B2 |
10709832 | Criado et al. | Jul 2020 | B2 |
10716482 | Anderson et al. | Jul 2020 | B2 |
10716583 | Look et al. | Jul 2020 | B2 |
10716880 | Culbert et al. | Jul 2020 | B2 |
10716915 | Ogle et al. | Jul 2020 | B2 |
10722238 | Sutton et al. | Jul 2020 | B2 |
10722239 | Chang | Jul 2020 | B2 |
10722251 | Garrison et al. | Jul 2020 | B2 |
10722253 | DeVille et al. | Jul 2020 | B2 |
10722255 | Leaker et al. | Jul 2020 | B2 |
10729455 | Goyal et al. | Aug 2020 | B2 |
10743893 | Garrison et al. | Aug 2020 | B2 |
10751159 | Janardhan et al. | Aug 2020 | B2 |
10772644 | Feltyberger et al. | Sep 2020 | B2 |
10772649 | Hansen et al. | Sep 2020 | B2 |
10779835 | Chang | Sep 2020 | B2 |
10779855 | Garrison | Sep 2020 | B2 |
10786270 | Yang et al. | Sep 2020 | B2 |
10792056 | Vale et al. | Oct 2020 | B2 |
10799331 | Hauser | Oct 2020 | B2 |
10828061 | Bonnette et al. | Nov 2020 | B2 |
10835257 | Ferrera et al. | Nov 2020 | B2 |
10835271 | Ma | Nov 2020 | B2 |
10835272 | Yang et al. | Nov 2020 | B2 |
10835278 | Wilke et al. | Nov 2020 | B2 |
10835711 | Yang et al. | Nov 2020 | B2 |
10864351 | Garrison et al. | Dec 2020 | B2 |
10864357 | Kume et al. | Dec 2020 | B2 |
10869956 | Torrance et al. | Dec 2020 | B2 |
10874410 | Scarpine et al. | Dec 2020 | B2 |
10874411 | Ngnyen et al. | Dec 2020 | B2 |
10888346 | Ulm, III | Jan 2021 | B2 |
10893881 | Dixon et al. | Jan 2021 | B2 |
10893978 | Sawicz | Jan 2021 | B2 |
10905448 | Machi | Feb 2021 | B2 |
10912577 | Marchand et al. | Feb 2021 | B2 |
10912871 | Gulcher et al. | Feb 2021 | B2 |
10922704 | Look et al. | Feb 2021 | B2 |
10932797 | Thomas | Mar 2021 | B2 |
10932810 | Malhi et al. | Mar 2021 | B2 |
10939931 | Grandfield et al. | Mar 2021 | B2 |
10952757 | Galdonik et al. | Mar 2021 | B2 |
10952882 | Chou et al. | Mar 2021 | B2 |
10959750 | Wallace | Mar 2021 | B2 |
10960178 | Savastano et al. | Mar 2021 | B2 |
10993731 | Leynov et al. | May 2021 | B2 |
11013523 | Arad Hadar | May 2021 | B2 |
11026709 | Greenhalgh et al. | Jun 2021 | B2 |
11027104 | Kume et al. | Jun 2021 | B2 |
11051832 | Look et al. | Jul 2021 | B2 |
11051978 | Heeren et al. | Jul 2021 | B2 |
11058445 | Cox et al. | Jul 2021 | B2 |
11058451 | Marchand et al. | Jul 2021 | B2 |
11065018 | Buck et al. | Jul 2021 | B2 |
11077288 | Govari | Aug 2021 | B2 |
11083485 | Kobayashi et al. | Aug 2021 | B2 |
11083559 | Kobayashi et al. | Aug 2021 | B2 |
11090070 | Fiorella et al. | Aug 2021 | B2 |
11090071 | Girdhar et al. | Aug 2021 | B2 |
11090466 | Nicholson | Aug 2021 | B1 |
11096703 | Panian | Aug 2021 | B2 |
11096712 | Teigen et al. | Aug 2021 | B2 |
11096715 | Hatta et al. | Aug 2021 | B2 |
11103265 | Wallace et al. | Aug 2021 | B2 |
11116528 | Wallace | Sep 2021 | B2 |
11123090 | Yang et al. | Sep 2021 | B2 |
11129629 | Welch et al. | Sep 2021 | B2 |
11147571 | Cox et al. | Oct 2021 | B2 |
11147949 | Yang et al. | Oct 2021 | B2 |
11160570 | Skujins et al. | Nov 2021 | B2 |
11160571 | Nguyen et al. | Nov 2021 | B2 |
11160572 | Ulm, III | Nov 2021 | B2 |
11185623 | Ovehinnikov et al. | Nov 2021 | B2 |
11185664 | Garrison et al. | Nov 2021 | B2 |
11191558 | Nguyen et al. | Dec 2021 | B2 |
11197683 | Teigen et al. | Dec 2021 | B1 |
11197977 | Mullins et al. | Dec 2021 | B2 |
11207096 | To et al. | Dec 2021 | B2 |
11207456 | Charron et al. | Dec 2021 | B2 |
11224458 | Savastano et al. | Jan 2022 | B2 |
11224721 | Garrison et al. | Jan 2022 | B2 |
11229445 | Ogle | Jan 2022 | B2 |
11229451 | Guerra et al. | Jan 2022 | B2 |
11229770 | Chou et al. | Jan 2022 | B2 |
11234723 | Ogle | Feb 2022 | B2 |
11253277 | Buck et al. | Feb 2022 | B2 |
11259820 | Walzman | Mar 2022 | B2 |
11259821 | Buck et al. | Mar 2022 | B2 |
11266434 | MeRae et al. | Mar 2022 | B2 |
11272945 | Shrivastava et al. | Mar 2022 | B2 |
20030187475 | Tsugita et al. | Oct 2003 | A1 |
20050004594 | Nool | Jan 2005 | A1 |
20050020973 | MacMahon | Jan 2005 | A1 |
20050159716 | Kobayashi | Jul 2005 | A1 |
20050228423 | Khashayar et al. | Oct 2005 | A1 |
20050240146 | Nash et al. | Oct 2005 | A1 |
20070075161 | Ivri | Apr 2007 | A1 |
20070129679 | Bonnette et al. | Jun 2007 | A1 |
20070135779 | Lalomia et al. | Jun 2007 | A1 |
20070239182 | Glines | Oct 2007 | A1 |
20080103433 | Nazarifar et al. | May 2008 | A1 |
20080147023 | Hopkins et al. | Jun 2008 | A1 |
20100185150 | Zacharias | Jul 2010 | A1 |
20100191169 | Chang | Jul 2010 | A1 |
20100191170 | Chang | Jul 2010 | A1 |
20100204672 | Lockhart | Aug 2010 | A1 |
20110166496 | Criado et al. | Jul 2011 | A1 |
20120041360 | Gerg et al. | Feb 2012 | A1 |
20120059340 | Larsson | Mar 2012 | A1 |
20130150782 | Sorensen | Jun 2013 | A1 |
20130267919 | Caso et al. | Oct 2013 | A1 |
20140271273 | Carpenter | Sep 2014 | A1 |
20140303658 | Bonnette et al. | Oct 2014 | A1 |
20140323906 | Peatfield et al. | Oct 2014 | A1 |
20150283309 | Look et al. | Oct 2015 | A1 |
20150327875 | Look et al. | Nov 2015 | A1 |
20160089227 | Loh | Mar 2016 | A1 |
20160128869 | Zacharias | May 2016 | A1 |
20160296690 | Kume et al. | Oct 2016 | A1 |
20160367272 | Garrison et al. | Dec 2016 | A1 |
20170043066 | Laub | Feb 2017 | A1 |
20170100142 | Look et al. | Apr 2017 | A1 |
20170181760 | Look | Jun 2017 | A1 |
20170239447 | Yang et al. | Aug 2017 | A1 |
20170368309 | Garrison et al. | Dec 2017 | A1 |
20180028359 | Gordon et al. | Feb 2018 | A1 |
20180049920 | Charles | Feb 2018 | A1 |
20180207397 | Look et al. | Jul 2018 | A1 |
20180256177 | Cooper et al. | Sep 2018 | A1 |
20180353194 | Shaffer et al. | Dec 2018 | A1 |
20190108540 | Look et al. | Apr 2019 | A1 |
20190125512 | Macdonald et al. | May 2019 | A1 |
20190133616 | Sachar et al. | May 2019 | A1 |
20190133617 | Look et al. | May 2019 | A1 |
20190142567 | Janardhan et al. | May 2019 | A1 |
20190142568 | Janardhan et al. | May 2019 | A1 |
20190167287 | Vale et al. | Jun 2019 | A1 |
20190167406 | Janardhan et al. | Jun 2019 | A1 |
20190209745 | Hanson et al. | Jul 2019 | A1 |
20190216476 | Bose et al. | Jul 2019 | A1 |
20190239910 | Brady et al. | Aug 2019 | A1 |
20190262120 | Walzman | Aug 2019 | A1 |
20190274704 | Jenson et al. | Sep 2019 | A1 |
20190307947 | Stubkjaer | Oct 2019 | A1 |
20190328410 | Look et al. | Oct 2019 | A1 |
20190350604 | Slee et al. | Nov 2019 | A1 |
20190351182 | Chou et al. | Nov 2019 | A1 |
20190366042 | Garrison et al. | Dec 2019 | A1 |
20190374128 | Palushi et al. | Dec 2019 | A1 |
20190381223 | Culbert et al. | Dec 2019 | A1 |
20190381303 | Angel et al. | Dec 2019 | A1 |
20190388109 | Cai | Dec 2019 | A1 |
20200015826 | Chang | Jan 2020 | A1 |
20200015840 | Mallaby | Jan 2020 | A1 |
20200016369 | Garrison et al. | Jan 2020 | A1 |
20200022711 | Look et al. | Jan 2020 | A1 |
20200022712 | Deville et al. | Jan 2020 | A1 |
20200023160 | Chou et al. | Jan 2020 | A1 |
20200023164 | Tran et al. | Jan 2020 | A1 |
20200029998 | Ogle et al. | Jan 2020 | A1 |
20200038576 | Garrison et al. | Feb 2020 | A1 |
20200046368 | Merritt et al. | Feb 2020 | A1 |
20200046389 | Galdonik et al. | Feb 2020 | A1 |
20200046939 | Garrison et al. | Feb 2020 | A1 |
20200046940 | Garrison et al. | Feb 2020 | A1 |
20200078029 | Hansen et al. | Mar 2020 | A1 |
20200086083 | Porter et al. | Mar 2020 | A1 |
20200093503 | Deville et al. | Mar 2020 | A1 |
20200121336 | Tsukamoto et al. | Apr 2020 | A1 |
20200121356 | Look et al. | Apr 2020 | A1 |
20200155178 | Culbert et al. | May 2020 | A1 |
20200164178 | Garrison et al. | May 2020 | A1 |
20200170666 | Trosper et al. | Jun 2020 | A1 |
20200179576 | Wood | Jun 2020 | A1 |
20200179578 | Look et al. | Jun 2020 | A1 |
20200187965 | Garrison et al. | Jun 2020 | A1 |
20200187979 | Bowman | Jun 2020 | A1 |
20200205840 | Adawi et al. | Jul 2020 | A1 |
20200206457 | Boling | Jul 2020 | A1 |
20200206458 | Mullins et al. | Jul 2020 | A1 |
20200214726 | Anand et al. | Jul 2020 | A1 |
20200215306 | Garrison et al. | Jul 2020 | A1 |
20200246014 | Walzman | Aug 2020 | A1 |
20200253624 | Gamba et al. | Aug 2020 | A1 |
20200276411 | Ogle et al. | Sep 2020 | A1 |
20200281610 | Look et al. | Sep 2020 | A1 |
20200281611 | Kelly et al. | Sep 2020 | A1 |
20200289136 | Chou | Sep 2020 | A1 |
20200289722 | Culbert et al. | Sep 2020 | A1 |
20200297362 | DeVille et al. | Sep 2020 | A1 |
20200297363 | Look et al. | Sep 2020 | A1 |
20200297365 | Bowman et al. | Sep 2020 | A1 |
20200297410 | Nguyen et al. | Sep 2020 | A1 |
20200297912 | Criado et al. | Sep 2020 | A1 |
20200315642 | Greenhalgh et al. | Oct 2020 | A1 |
20200316348 | Ascher et al. | Oct 2020 | A1 |
20200324079 | Jalgaonkar et al. | Oct 2020 | A1 |
20200337716 | Garrison et al. | Oct 2020 | A1 |
20200345904 | Casey et al. | Nov 2020 | A1 |
20200345981 | Garrison et al. | Nov 2020 | A1 |
20200352583 | Goyal et al. | Nov 2020 | A1 |
20200367917 | Teigen et al. | Nov 2020 | A1 |
20200375616 | Fitz et al. | Dec 2020 | A1 |
20200376175 | Hartwell | Dec 2020 | A1 |
20200383698 | Miao et al. | Dec 2020 | A1 |
20200397446 | Chang | Dec 2020 | A1 |
20200397451 | Feltyberger et al. | Dec 2020 | A1 |
20200397452 | Twomey et al. | Dec 2020 | A1 |
20200397465 | Nakano et al. | Dec 2020 | A1 |
20200397957 | Teigen et al. | Dec 2020 | A1 |
20210022843 | Hauser | Jan 2021 | A1 |
20210038236 | Ma | Feb 2021 | A1 |
20210038779 | Lorenzo | Feb 2021 | A1 |
20210045758 | Garrison et al. | Feb 2021 | A1 |
20210045760 | Ulm, III | Feb 2021 | A1 |
20210052296 | Garrison | Feb 2021 | A1 |
20210068861 | Bonnette et al. | Mar 2021 | A1 |
20210069467 | Garrison et al. | Mar 2021 | A1 |
20210069468 | Keating et al. | Mar 2021 | A1 |
20210077116 | Ferrera et al. | Mar 2021 | A1 |
20210077134 | Vale et al. | Mar 2021 | A1 |
20210085348 | Nguyen | Mar 2021 | A1 |
20210085931 | Green et al. | Mar 2021 | A1 |
20210093344 | Janardhan et al. | Apr 2021 | A1 |
20210100974 | Walzman | Apr 2021 | A1 |
20210100987 | Sehultz et al. | Apr 2021 | A1 |
20210110419 | Look et al. | Apr 2021 | A1 |
20210113224 | Dinh | Apr 2021 | A1 |
20210121281 | Walzman | Apr 2021 | A1 |
20210128182 | Teigen et al. | May 2021 | A1 |
20210128893 | Twomey et al. | May 2021 | A1 |
20210138193 | Garrison et al. | May 2021 | A1 |
20210138194 | Garrison et al. | May 2021 | A1 |
20210153883 | Casey et al. | May 2021 | A1 |
20210161544 | Casey | Jun 2021 | A1 |
20210161639 | Walzman | Jun 2021 | A1 |
20210169509 | Goyal | Jun 2021 | A1 |
20210170148 | Green et al. | Jun 2021 | A1 |
20210186534 | Hunt et al. | Jun 2021 | A1 |
20210219998 | Thomas | Jul 2021 | A1 |
20210220109 | Walzman | Jul 2021 | A1 |
20210220528 | Jalgaonkar et al. | Jul 2021 | A1 |
20210228222 | Porter | Jul 2021 | A1 |
20210228844 | Ogle | Jul 2021 | A1 |
20210228847 | Kume et al. | Jul 2021 | A1 |
20210236148 | Marchand et al. | Aug 2021 | A1 |
20210236150 | Arad Hadar | Aug 2021 | A1 |
20210236257 | Walzman | Aug 2021 | A1 |
20210259719 | Griffin | Aug 2021 | A1 |
20210267745 | Walzman | Sep 2021 | A1 |
20210275197 | Vale et al. | Sep 2021 | A1 |
20210298773 | Echarri et al. | Sep 2021 | A1 |
20210298775 | Nguyen et al. | Sep 2021 | A1 |
20210299343 | Criado et al. | Sep 2021 | A1 |
20210322051 | Hatta et al. | Oct 2021 | A1 |
20210322053 | Kobayashi et al. | Oct 2021 | A1 |
20210322738 | Kume et al. | Oct 2021 | A1 |
20210330332 | Chou et al. | Oct 2021 | A1 |
20210338255 | Alesi et al. | Nov 2021 | A1 |
20210346040 | Panian | Nov 2021 | A1 |
20210353314 | Porter | Nov 2021 | A1 |
20210353316 | Wallace et al. | Nov 2021 | A1 |
20210353323 | Teigen et al. | Nov 2021 | A1 |
20210361305 | Mogi et al. | Nov 2021 | A1 |
20210378691 | Panian | Dec 2021 | A1 |
20210378696 | Yang et al. | Dec 2021 | A1 |
20210393280 | Cortinas Villazon et al. | Dec 2021 | A1 |
20220000500 | Arad Hadar et al. | Jan 2022 | A1 |
20220000502 | Ulm, III et al. | Jan 2022 | A1 |
20220000505 | Hauser | Jan 2022 | A1 |
20220000506 | Hauser | Jan 2022 | A1 |
20220000507 | Hauser | Jan 2022 | A1 |
20220008090 | Look et al. | Jan 2022 | A1 |
20220015798 | Marchand et al. | Jan 2022 | A1 |
20220022898 | Cox et al. | Jan 2022 | A1 |
20220022899 | Girdhar et al. | Jan 2022 | A1 |
20220022900 | Nguyen et al. | Jan 2022 | A1 |
20220031931 | Stout | Feb 2022 | A1 |
20220054150 | Dholakia et al. | Feb 2022 | A1 |
20220054151 | Shiffette | Feb 2022 | A1 |
20220054153 | Albers et al. | Feb 2022 | A1 |
20220061870 | Mintz | Mar 2022 | A1 |
20220061871 | Mintz | Mar 2022 | A1 |
20220061872 | Mintz | Mar 2022 | A1 |
20220062588 | Mintz | Mar 2022 | A1 |
20220087696 | Maini et al. | Mar 2022 | A1 |
20220168000 | Naglreiter et al. | Jun 2022 | A1 |
20220338887 | Nair et al. | Oct 2022 | A1 |
Number | Date | Country |
---|---|---|
215386236 | Jan 2022 | CN |
1996001079 | Jan 1996 | WO |
2009012473 | Jan 2009 | WO |
2008157674 | Dec 2009 | WO |
2010075445 | Jul 2010 | WO |
2013064852 | May 2013 | WO |
20140151209 | Sep 2014 | WO |
2017062927 | Apr 2017 | WO |
2018019829 | Feb 2018 | WO |
2019213179 | Nov 2019 | WO |
2020023541 | Jan 2020 | WO |
20200145928 | Jul 2020 | WO |
20200167276 | Aug 2020 | WO |
2021012058 | Jan 2021 | WO |
2021016213 | Jan 2021 | WO |
2021073572 | Apr 2021 | WO |
2021083832 | May 2021 | WO |
2021113962 | Jun 2021 | WO |
2021113970 | Jun 2021 | WO |
2021123395 | Jun 2021 | WO |
2021151969 | Aug 2021 | WO |
2021178696 | Sep 2021 | WO |
2021242963 | Dec 2021 | WO |
20210250133 | Dec 2021 | WO |
2022020366 | Jan 2022 | WO |
2022040615 | Feb 2022 | WO |
2022174175 | Aug 2022 | WO |
2023092042 | May 2023 | WO |
Entry |
---|
US 11,191,563 B2, 12/2021, Savastano et al. (withdrawn) |
International Search Report and Written Opinion issued for Application No. PCT/US2022/025918, dated Jun. 29, 2022. |
Office Action issued for U.S. Appl. No. 17/726,787, dated Sep. 20, 2022. |
Office Action issued for U.S. Appl. No. 17/726,787, dated Dec. 1, 2022. |
Notice of Allowance issued for U.S. Appl. No. 17/726,787, dated Apr. 27, 2023. |
Office Action issued for U.S. Appl. No. 17/726,788, dated Aug. 9, 2022. |
Office Action issued for U.S. Appl. No. 17/726,788, dated Dec. 1, 2022. |
Notice of Allowance issued for U.S. Appl. No. 17/726,788, dated May 5, 2023. |
Office Action issued for U.S. Appl. No. 17/726,791, dated Jul. 26, 2022. |
Office Action issued for U.S. Appl. No. 17/726,791, dated Nov. 30, 2022. |
Notice of Allowance issued for U.S. Appl. No. 17/726,791, dated Apr. 23, 2023. |
Number | Date | Country | |
---|---|---|---|
20230256155 A1 | Aug 2023 | US |
Number | Date | Country | |
---|---|---|---|
63180291 | Apr 2021 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17726791 | Apr 2022 | US |
Child | 18140280 | US |